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 Autophagy is a catabolic process that normally utilizes the lysosome. With central 
roles in survival during stress and protein and organelle turnover, the far-reaching 
implications of this system in disease are being increasingly understood. Studying 
autophagy is complicated by its role in cell survival and programmed cell death and the 
involvement of the canonical marker of autophagy, Atg8/LC3, in numerous non-
autophagic roles.  
 The malaria parasite, Plasmodium, has conserved certain aspects of the 
autophagic machinery but for what purpose has long remained a mystery. Major 
advances have recently been gained and suggest a role for Atg8 in apicoplast 
maintenance, degradation of heme inside the food vacuole, and possibly trafficking of 
proteins or organelles outside the parasite membrane.  
 Malaria kills nearly a million people each year, mostly children, representing a 
global public health problem. With ninety percent of these deaths in Africa, malaria also 
represents a major obstacle to the stability and economic prosperity of the nation. The 
essentiality of plasmodial Atg8, and its emerging role at the essential apicoplast organelle 
implicate Atg8 as a good drug target for antimalarial drug design. Atg8 is an ubiquitin-
like protein, requiring an E1-activating and E2-conjugating enzyme for lipidation to 
membranes, required for its function. An important question is how the conjugation 
systems differ between Plasmodium and humans and how these differences can be 
exploited to design specific novel antimalarial drugs. We provide structural information 
 iii
on the P. falciparum Atg8-Atg3 interaction, identify small molecule inhibitors against the 
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 There are many public health problems facing the world: cancer, AIDS, 
neurodegenerative disease, and increasingly diabetes. In contrast, malaria is a disease 
most Americans likely only become aware of when preparing to travel abroad. So why 
should one care about a disease that already has existing treatments and whose impact is 
constrained to the developing world?  
 One could counter with the global impact of the disease; half the world’s 
population is at risk of malaria and in 2010 there were 219 million clinical cases and 
660,000 deaths from malaria (1). Because of the confounding nature of the disease and 
the lack of access to health care in many regions, especially in Africa, the number of 
cases is most likely underestimated. What is lost in the numbers is the human face; 86% 
of victims are under 5 years of age (1). Pregnant women are especially susceptible to 
malaria, which accounts for 8-14% of low weight births in malaria-endemic regions, a 
poor indicator for the future health of that child (2). Additionally, the economic toll of the 
disease is astounding. Poverty is a positive indicator for malaria prevalence and 
mortality; countries with lower gross national incomes have higher malaria mortality 
rates and within countries, children from poorer families are more likely to die from the 
disease (3). Malaria prevents children from attending school and adults from working 
continuing the cycle of malaria and poverty.   
 Artemisinin combination therapy is the first-line defense for P. falciparum-
causing malaria in most countries. As was the case for previous antimalarials, such as 
chloroquine, resistance is emerging against artemisinin and has been detected in 4 
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countries in Southeast Asia (1). We are in a never-ending arms race with the malaria 
parasite and it is pivotal to have new and effective therapies ready when resistance 
inevitably spreads to other parts of the world. Finally, many antimalarials have severe 
side effects including insomnia, intense itchiness, psychosis, sunburn, and blindness (4-
8). Treatment for the hypnozoite-causing species, P. vivax, requires Primaquine, which 
causes hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency (9). 
 There is great hope, along with great skepticism, for a malaria vaccine. The most 
furthest candidate, RTS,S, is in Phase 3 clinical trials (10). This vaccine targets P. 
falciparum, leaving large swaths of the world unprotected, where P. vivax is the 
predominant malaria-causing species. Additionally the vaccine offers partial protection 
that is far from optimal. Although promising vaccine targets are in the pipeline (11), there 
is a need for development of new antimalarial drugs for the foreseeable future.  
 
The Plasmodium Parasite 
 
 The Plasmodium parasite is a unicellular eukaryote that has evolved distinctive 
biological mechanisms to invade and replicate within different cell types in both the 
mosquito vector and mammalian host as part of its life cycle (Figure 1.1). During a 
mosquito blood meal, elongated sporozoites are injected into the host and invade liver 
cells. Here, the parasite undergoes major morphological changes, transforming from an 
elongated structure into a round trophozoite (12, 13). Rhoptries and dense granules, as 
well as other organelles believed to be unnecessary after initial host invasion, are 
degraded shortly after parasite metamorphosis within the liver (13). The parasite uses a 
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form of asexual replication, schizogony, to produce hundreds to thousands of teardrop-
shaped merozoites. Extensive remodeling of the host cell creates a merosome, which 
contains the merozoites that are released into the bloodstream to continue the next stage 
of infection, the symptomatic erythrocytic stage (14, 15).  
 Merozoites invade the red blood cells (RBC) and develop into the ring stage form. 
This continues to the active feeding, or trophozoite stage before undergoing schizogony 
to produce more merozoites for sequential rounds of invasion and replication. During the 
trophic stage, hemoglobin is taken up from the host RBC cytoplasm and transported to 
the food vacuole (FV), a lysosome-like compartment where it is degraded to provide 
amino acids for parasite growth. Some merozoites are shunted from this cycle to produce 
gametocytes, which are subsequently taken up by a mosquito during a blood meal, 
continuing the Plasmodium life cycle.  
 All members of the phylum Apicomplexa, with the exception of Cryptosporidium, 
contain apicoplasts, plastid organelles analogous to chloroplasts in plants, acquired 
through endosymbiosis. The organelle is essential to Plasmodium survival in both asexual 
stages and is the site for synthesis of iron-sulfur clusters, isoprenoids, and fatty acids 
(16). It contains four membranes, requiring unique transport processes for trafficking 
proteins to the apicoplast lumen.  
 
Introduction to Autophagy 
 
 Classically, autophagy has been defined as a eukaryotic system for degradation of 
cellular material inside the lysosome. The best-studied form, macroautophagy, 
 5
encapsulates the cytoplasmic material inside a double-membrane vesicle, the 
autophagosome that fuses with the lysosome (Figure 1.2A). Once considered a 
nonselective bulk process, autophagy is now appreciated as a way to quickly respond to 
shifting cellular conditions and to selectively degrade damaged organelles, proteins, 
nucleic acids, and pathogens  
 The first mention of plasmodial autophagy in the literature was in the 1970s by 
D.C. Warhurst and colleagues. They conducted extensive studies showing increased 
pigment clumping in “autophagic vacuoles (AV)” following chloroquine (CQ) treatment 
in blood stage parasites (17, 18). In the 2000s, drug treatment was again reported to 
induce autophagic vacuoles and an autophagic cell death (19, 20). However, leading 
researchers in autophagy have warned against the visualization of autophagosomes 
through electron microscopy as the sole evidence for an autophagic process (21, 22). The 
difficulty in culturing certain stages of the parasite, genetically manipulating the 
organism to make conditional knockouts, and to clone and express genes recombinantly 
all have contributed to a void of knowledge in this area. The last year witnessed an 
expanse in papers exploring autophagic pathways in the Plasmodium parasite.  
 
Overview of autophagy  
 Although over 30 AuTophaGy (Atg) proteins have been identified in yeast, not all 
are essential to macroautophagy. Autophagy induction in yeast (and mammals) begins 
with the Atg1 (ULK1 in mammls) protein kinase complex, which is inhibited by the 
target of rapamycin ,TORC1 (mTOR in mammals) complex under homeostasis. Nutrient 
deprivation or rapamycin treatment alleviates the negative regulation on the Atg1 
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complex (23). Atg1 and Atg13 form a complex with Atg31/Atg17/Atg29/Atg11 in yeast, 
analogous to the ULK1/Atg13/FIP200/Atg101 complex in mammals, at the pre-
autophagosomal structure (PAS) (24, 25). Atg17 has been implicated as the most 
upstream scaffold for protein recruitment to the PAS (26). Phosphorylation of substrates 
by Atg1 activates the Phosphatidyl-Inositol 3-phosphate Kinase (PI3K) class III complex, 
composed of Vps34, Atg14, Vps15/p150, and Atg6 (Beclin1 in mammals) which 
converts phosphatidylinositol (PI) into phosphatidylinositol triphosphate (PI(3)P) at the 
site of the PAS (27). This creates a binding site for Atg18 (WIPIs in mammals) and Atg2 
at the isolation membrane, also requiring association with the transmembrane protein 
Atg9 (28).  
 Elongation of the membrane and closure of the autophagosome requires the 
ubiquitin (Ub)-like protein, Atg8 (LC3 in mammals), which is covalently attached via its 
C-terminal glycine to phosphatidylethanolamine (PE) in the phagophore membrane (29). 
Atg8 utilizes a similar conjugation pathway as Ub for lipidation, diagrammed in Figure 
1.2B. In most species, Atg8 is proteolytically activated by Atg4, then transferred to an 
E1-activating enzyme, Atg7, before transfer to its E2-conjugating enzyme, Atg3 for 
lipidation (30, 31). Another autophagy Ubl protein, Atg12, is covalently attached to Atg5, 
requiring Atg7 as well, and its own E2, Atg10 (32). The Atg12-Atg5 conjugate forms a 
complex with Atg16 to drastically increase conjugation of Atg8 through rearrangement of 
Atg3’s catalytic site (33, 34). The autophagosome seals and fuses with endocytic 
compartments and the lysosome where the material is broken down and recycled back to 
the cytoplasm.  
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Bioinformatics Search for Autophagy Proteins in Plasmodium 
 
 To obtain an overview of the system, we performed bioinformatics analysis to 
identify putative orthologues of autophagy proteins in Plasmodium falciparum. While 
such lists have been published, our analysis focused on the minimal machinery needed 
for macroautophagy in yeast (35-39). The coordination of events in macroautophagy is 
diagrammed in Figure 1.3, with putative homologues identified in Plasmodium colored in 
black and less reliable identifications in gray. Although several hits were identified for 
the nutrient sensor TOR, these hits have clearer homology to Phosphatidyl-Inositol 4-
Kinases. Of the proteins involved in autophagy induction, Atg1 and its mammalian 
binding partners, FIP200 and Atg101 appear to have orthologues in Plasmodium, while 
Atg13 appears absent. The C-terminal Atg13-binding domain is also missing from 
PfAtg1. It contains several potential Atg8-interacting motifs, which mediate Atg1 binding 
to Atg8 in an Atg13-independent manner in yeast and humans (40). PfPI3K exists in P. 
falciparum and is one of the better-characterized proteins. Vps15 and Atg14, members of 
the PI3K complex were identified. While Atg6 was not identified using our methods, it 
has recently been reported by Cervantes et al (41). 
 Atg9 is an essential transmembrane protein for autophagy thought to supply 
Golgi-derived membranes to the PAS during initiation (42, 43). None of the significant 
BLAST hits for Atg9 are predicted to contain any of its six transmembrane domains. 
Atg18 likely has a homologue in Plasmodium and contains the FRRG motif necessary for 
binding to PI(3)P and Atg18-Atg2 recruitment to the PAS as well as WD40 repeats for 
beta propeller formation. Atg18 is thought to aid recruitment of Atg8 to the PAS and 
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protect it from premature Atg4 cleavage (44). A putative homologue for Atg18’s binding 
partner, Atg2, was also identified but is annotated as a putative rhoptry protein.   
 Atg8, Atg7, and Atg3 orthologues are present (Figure 1.2C). Atg8 contains a C-
terminal glycine in Plasmodium (45). Similar Atg8 homologs have been identified in 
plants and other protists including Toxoplama (46, 47). Therefore, the putative Atg4 
orthologue is likely important for recycling improperly conjugated Atg8 (48). Putative 
homologues for the Ubl, Atg12 and its target, Atg5, were identified. However, the C-
terminal glycine of PfAtg12 and its E2 enzyme needed for covalent attachment are 
absent. It is unclear if Atg16, which forms a 350 kDa complex with Atg12-Atg5 is 
present. It is essential in vivo but not in vitro for Atg8 lipidation (33, 49).  
 Fusion of both autophagosomes and endosomes with the lysosome requires Rab7 
and various SNAREs (50, 51). Apicomplexans contain a basic set of Rabs, including 
Rab7 (52). Putative homologues for essential SNARES including Vti1b and VAMP8 also 
exist in Plasmodium. The lipase for breaking down the autophagosome membrane, Atg15 
(53) was absent in our search but is reported by another group (41). The vacuolar 
proteinase Prb1 (53, 54) was also not found, however the parasite contains numerous 
proteases in the food vacuole for degrading hemoglobin. The lysosomal amino acid 
efflux pump Atg22 is present (55). More information, including the PlasmoDB code of 
hits and e-values are presented in the appendix (Table A.1). 
 
Expression data for autophagy genes  
 PlasmoDB houses RNA-Seq data during the blood stage for each gene (56). 
Additionally, several widespread mass spectrometry studies have provided data on 
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protein expression in the liver and blood stages (57-62). There is also specific transcript, 
immunoblotting and/or immunofluorescence data for a small subset of autophagy genes 
(38, 39, 63-65). Evidence for expression from these various sources is compiled in Figure 
1.4 and supports an important role for autophagy proteins during the late blood stage, 
where both hemoglobin digestion and apicoplast growth is maximal. Less data is 
available for non-blood stages. Atg8, Atg3, and Atg7 are transcribed during all life cycles 
of P. berghei (64). 
 
Recent Advances in the Study of Atg8 in Plasmodium 
 
Localization of the autophagy marker, Atg8 in Plasmodium 
 Atg8/LC3 is the classical marker for autophagy as it is covalently attached to the 
pre-autophagosome (PAS) membrane at an early stage and stays conjugated to the 
autophagosome during fusion with the lysosome. In yeast and mammals, Atg8/LC3 has a 
diffuse cytoplasmic distribution under nutrient rich conditions but forms punctate upon 
autophagy induction (30). The lipidated fraction of Atg8 can also be visualized as a faster 
migrating band with high percentage or urea-containing gels in SDS-PAGE (31).  
 Several groups have examined the localization of Atg8 in different Plasmodium 
species and stages.  Under normal conditions, P. berghei liver and P. falciparum blood 
stage Atg8 are in punctae that are nearby and partially colocalize with the apicoplast 
markers, such as acyl-carrier protein (ACP) (38, 39, 64, 66). Localization to other 
organelles, such as mitochondria, rhoptries, micronemes, and dense granules was 
negative in the schizont, while transgenic Atg8 lacking the C-terminal glycine for 
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lipidation showed diffuse localization, validating the results of these studies (38). In 
hepatocytes, PbAtg8 localization along the apicoplast was observed 14 hours post-
invasion and increased with organelle size throughout the liver stage (64).  
 Roepe and Sinai also observe punctate PfAtg8 in blood stage trophozoites, but co-
localization with ACP, or other organelle markers, was not assessed (67). Interestingly, 
when cells were transferred to media lacking amino acids and glucose for 6 hours, 
PfAtg8 redistributes to a wider punctate staining that seems to be inside the host red 
blood cell cytoplasm. Similar re-localization was seen in treatment with high levels of 
CQ (67). Langsley and colleagues also starved blood stage parasites in media lacking 
amino acids. At 4 hours, they observed localization of PfAtg8 to double-membrane 
structures also containing PfRab7, required for autophagosome-lysosome fusion in other 
species, that were near or inside the food vacuole, visualized with electron micrographs 
(66). This has thus far, provided the strongest evidence for autophagic process where the 
food vacuole is the final digestive compartment in a Plasmodium. 
 Less attention has been paid to the mosquito stages, however PfAtg8 shows 
elongated tubular localization in mosquito midgut oocytes and sporozoites from the 
mosquito salivary glands. This staining is reminiscent of apicoplast morphology under 
normal cell conditions (64). 
 
Atg8 is essential for Plasmodium 
 Knockout of Atg8 is lethal in the mouse malaria model, P. yoelli (68). In the 
highly related Apicomplexa, Toxoplasma, the E2 conjugating enzyme for Atg8, TgAtg3, 
is also indispensable (47). It was recently shown that attenuation of PfAtg7, the E2 
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enzyme necessary for Atg8 lipidation, led to a severe growth defect of P. falciparum 
blood stages (65). Consistent with this, a fraction of Plasmodium Atg8 is lipidated in 
blood stages and is necessary for localization to the apicoplast (38, 66, 69).   
 
Potential Functions for Atg8 in Plasmodium 
 Atg8’s essentiality in Plasmodium is intriguing, as Atg8 knockouts are viable in 
yeast under homeostatic conditions (29), which suggests an alternative or additional vital 
function(s) in the parasite. Proposed roles include vesicular trafficking, growth and 
maintenance of the apicoplast, and programmed cell death.  
 
Hemoglobin degradation and autophagy  
 In early to mid-trophozoite stages, host cytoplasm is endocytosed, delivering 
hemoglobin to the food vacuole, for subsequent generation of amino acids. It has long 
been reported that CQ treatment led to production of vesicles inside the Plasmodium 
parasite (18, 19), which were assumed to be autophagic vesicles.  Chloroquine (CQ) is a 
lysosomatropic agent that prevents autophagosome-lysosome fusion (70, 71). In other 
studied Eukarya, CQ causes an accumulation of Atg8 lipidated to autophagosomes in 
starvation and non-starvation conditions (70). A longstanding antimalarial, CQ 
accumulates in the food vacuole and prevents hemozoin dimerization and hemoglobin 
digestion (72), starving the parasite of amino acids.  
 Varying responses are observed in Plasmodium upon CQ treatment and this 
appears to be due in part to the concentration that is used and the duration of treatment. In 
CQ-sensitive strains, such as 3D7, ten to 100 nM is cytostatic whereas micromolar 
amounts are cytocidal (73). Extended incubation (12 hours) with 120 nM CQ leads to a 
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build-up of hemoglobin-containing vesicles, (74) likely by preventing fusion of these 
vesicles with the food vacuole, preventing hemoglobin digestion and starving the parasite 
of amino acids. Sinai and Roepe report drastic re-localization of PfAtg8 from the parasite 
to the RBC host cytoplasm with either prolonged starvation or high cytocidal 
concentrations of CQ (67). The authors hypothesize that PfAtg8 may be involved in 
vesicular trafficking of hemoglobin or other nutrients under starvation conditions.  
 In contrast, Kitamura et al. do not see a change in PfAtg8 localization or protein 
levels in response to 300 nM CQ treatment. However these concentrations are cytostatic, 
and may not be sufficient to induce a lysosomatrophic effect; 100 µM is typically used in 
mammalian cell lines to block autophagy (73). Additionally the treatment period was 
shorter than in other studies.  
 Recently, immuno-EM and IFA studies show re-localization of PfAtg8 to Rab7-
containing vesicles near and inside the food vacuole when parasites are deprived of 
amino acids for 4 hours, providing the strongest evidence for an autophagic process (66). 
While these authors never saw PfAtg8 in the host cytoplasm, Cervantes et al. report some 
Atg8 staining in the RBC even under normal conditions (41). 
 Vps34, also known as class III PI3K, is a lipid kinase at the ER that produces 
PI(3)P on the outer leaflet, important for recruitment of proteins to the phagophore and 
proper curvature of the autophagosome (26, 75). PfVps34 purified from parasite lysate 
has kinase activity that can be inhibited by the well-characterized class III PI3K complex 
inhibitor, wortmannin. Endogenous PfVps34 localizes to the food vacuole and vesicular 
structures near the host plasma membrane in the blood stage (63). Strikingly, the PI3K 
inhibitor, wortmannin (10 µM, 5 hour treatment), caused accumulation of hemoglobin-
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containing endocytic vesicles within the parasite and subsequently less in the FV, 
indicating a defect in digestion concomitant with decreased parasite growth. They suggest 
the class III PI3K complex is important for hemoglobin endocytosis and trafficking to the 
FV in Plasmodium (63). While the effect of wortmannin on Plasmodium Atg8 was 
examined under normal conditions, it was not tested under starvation conditions to see if 
treatment prevented PfAtg8 localization to vesicles and the FV. However another PI3K 
inhibitor, 3-MA, inhibited re-localization of PfAtg8 to the host cytoplasm upon starvation 
or CQ treatment, implicating involvement of Atg8 in trafficking of theses hemoglobin-
containing vesicles (69).  
 The malaria parasite does not obtain isoleucine from hemoglobin and is 
dependent on the host for this amino acid. Plasmodium can survive up to 72 hours 
without exogenous isoleucine, suggesting a survival mechanism is present. Since food 
vacuole proteases are essential to survival, an autophagic mechanism was suggested (76).  
 While two independent studies concluded that P. berghei Atg8 could not 
complement an Atg8 knockout in yeast, a recent study showed P. falciparum Atg8 to be a 
functional homologue for ScAtg8 (38, 64, 66). This discrepancy between the species is 
unexpected as P. berghei and P. falciparum Atg8 are 88% identical to each other and 
40% identical to yeast Atg8. Transgenic PfAtg8 was not lipidated in mammalian cells, 
indicating PfAtg8 cannot complement the human homologue and PfAtg3 could not 
interact with human LC3 (45, 64). 
 
Vesicular Trafficking   
 Protein Secretion: The Plasmodium parasite initiates extensive remodeling of the 
host cell upon infection by exporting hundreds of its own proteins into the host cell. 
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Plasmodium is encapsulated by a parasitopherous vacuole (PV) within host cells. Proteins 
targeted for export to the host cytosol or plasma membrane must be trafficked out of the 
parasite plasma membrane and the PV, necessitating novel pathways for protein 
secretion. How this is done is still under extensive study, but one possibility is 
unconventional protein secretion, termed exophagy (77).  
 A recent review suggests that vesicles originating at the ER via the formation of 
PI(3)P are destined for export to the host cytoplasm (78). PfPI3K partially co-localizes 
with exported membrane protein 1 (PfEMP1), a virulence factor in P. falciparum that is 
exported to the erythrocyte surface (63). One of the more characterized routes of protein 
export beyond the PV utilizes a PEXEL motif for recognition. Recently, PI(3)P was 
shown to bind the PEXEL motif at PI(3)P-enriched regions in the ER (79). PfAtg8 
localization in the RBC cytoplasm is reported, but only under starvation conditions (67) 
and co-localization with PfEMP1 or the Maurer’s cleft (MC), an intermediate 
compartment for protein export in the RBC cytoplasm, was not examined. 
 Protein trafficking to the food vacuole: PI(3)P, is enriched at both the apicoplast 
and the food vacuole and one of the few PI(3)P-binding proteins identified in 
Plasmodium, FCP protein, is trafficked to the FV using an unknown mechanism, which 
some suggest may be similar to the autophagic cytoplasm-to-vacuole targeting pathway 
in yeast (80). Support is garnered by the presence of Atg8 vesicles in and near the food 
vacuole (66). 
  Organelle expulsion: The malaria parasite undergoes major morphological 
changes in the early liver stage, converting from a motile, slender sporozoite into a round 
trophozoite. During this transformation, organelles used for liver cell invasion, including 
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the inner membrane complex, rhoptries, and micronemes, are expelled from the parasites 
(12). Treatment of Plasmodium sporozoites with 3-methyladenine (3-MA), which targets 
Vps34, needed for PI(3)P production and phagophore formation, delays conversion into 
trophozoites (81). Electron micrographs of liver stage parasites revealed double-
membraned structures morphologically similar to autophagosomes containing 
micronemes leading to the hypothesis that exophagy of organelles could be important for 
differentiation in the liver stage in the absence of an extensive intracellular degradative 
system (36). 
 
Programmed cell death  
 Programmed cell death (PCD) is increasingly being examined in protozoans as a 
way to modulate host-pathogen responses and limit parasite load (82). Autophagy is a 
recognized mechanism of cell death in other eukarya where the balance between pro-
survival and pro-death is tightly regulated (83). Autophagic cell death has previously 
been reported for the protozoan parasites Toxoplasma and trypanosomes and less 
conclusively in Leishmania, but there is controversy as to the legitimacy of a regulated 
rather than incidental mechanism of cell death in protozoa (84-88). 
 Treatment of P. falciparum erythrocytes with chloroquine (180 nM), SNAP, a 
nitric oxide donor, and staurosporine, an apoptosis inducing agent, led to cell death that 
was described as autophagic-like because of distinct vacuolarization of the parasite 
cytoplasm and presence of double-membrane structures, whereas the nuclear morphology 
remained in tact and other apoptotic markers were absent (19). The morphology of this 
cell death is similar to that observed in retinal pigment epithelial cells upon treatment 
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with much higher concentrations (120 µM) of CQ and is thought to be the mechanism for 
retinotoxicity associated with CQ. In this case, they also did not see hallmarks of 
apoptosis but did see increased lipidation of LC3 to autophagic vacuoles and a block in 
degradation of the autophagy-specific substrate, p62 (89). Autophagic vacuoles were also 
observed in P. berghei blood stage parasites dying after treatment with 
dihydroartemisinin (20). In this study, the authors concluded, “Since the food vacuole 
membranes were affected, the nutrition of parasites was blocked and the autophagic 
vacuoles formed quickly as a result of amino-acid hunger of parasites.” However 
distribution of Atg8 was not investigated.  
 After invasion of hepatocytes, a significant fraction of P. berghei parasites die 
through an autophagic mechanism (38). This was observed in cell culture and in mice, 
indicating it is a physiological mechanism. The process is restricted to the later stages of 
development. Eickel et al. described double membrane structures that appeared similar to 
those reported by Meis and Verhave in 1985, then portrayed as “membranous whorls” 
(13). Yet, fluorescence microscopy revealed that PbAtg8 never localized to these 
vesicular structures and remained associated with the apicoplast, determined by 
colocalization with ACP, and its organellar fragments throughout the cell death event 
(38). Treatment with rapamycin (500 nM), which potently induces autophagy in yeast 
through inhibition of TOR, decreased parasite size and changed apicoplast morphology, 
but did not affect PbAtg8 localization. However, there is no known TOR orthologue in 
Plasmodium, and the observed effect on parasite growth could be mediated through off-
target effects or effects on host autophagy (90). The authors speculate that autophagy 
occurs in the parasite but is independent of Atg8. Although Atg8 is the canonical 
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autophagic marker, there are reports of macroautophagy that is independent of LC3 
conjugation (91). This alternative pathway requires ULK1, Rab9, and Beclin 1; of which 
there may be orthologues in Plasmodium (41). 
 
Apicoplast maintenance  
 The apicoplast is vital to survival in both mammalian stages. A gradual increase 
in apicoplast size begins in the trophozoite stage. Dramatic elongation and branching of 
the organelle occurs in the late trophozoite/early schizont stage. Division of the 
apicoplast occurs late in the schizont and ultimately results in each merozoite containing 
one apicoplast (92). If the autophagic machinery delivers lipids or proteins to the growing 
apicoplast membrane, the expression of its component proteins is necessary by the 
trophozoite stage. As shown in Figure 2, this appears to be the case.  
 Pf/PbAtg8 localizes to the apicoplast in liver and blood stages under normal 
conditions. Electron micrographs and biochemical data indicate that Atg8 is conjugated 
to the outermost membrane of the apicoplast (39). Plasmodium treated with 
chloramphenicol leads to loss of the apicoplast, which is normally lethal, but 
supplementation with isopentenylpyrophosphate (IPP) allows the parasite to survive 
during the RBC stage (93). Tomlins et al. observed PfAtg8 localization under these 
conditions. Strikingly, PfAtg8 was located at vesicular structures that also contained the 
apicoplast-targeted protein LipDH1, suggesting a role in trafficking (66). 
 Treatment of parasites with the Vps34 inhibitor, wortmannin (10 µM), did not 
change the localization of PfAtg8 at the apicoplast in the blood or liver stage suggesting 
Atg8 localization to the apicoplast is constitutive and not induced by the class III PI3K 
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complex (39, 66). However PfVps34 is also located at the apicoplast and its product, 
PI(3)P, is enriched at the apicoplast and nearby single-membrane vesicles, in addition to 
the food vacuole (94). PI(3)P production is maximal in later blood stages and Tawk et al. 
suggest that PI(3)P vesicles transport lipids or proteins to the apicoplast, as is the case in 
T. gondii (95). In agreement with this vital role, PI3K is essential in P. berghei (94). As 
of now, there are no studies describing co-localization between PI3K and Atg8.    
 Interestingly, although PbAtg8 localized to the apicoplast in the liver stage, its E1 
activating and E2 conjugating enzyme, Atg7 and Atg3, were located at the mitochondria, 
leading the authors to question whether they interact with PbAtg8 (38). However, 
localization was only described at 52 h.p.i., at which point PbAtg8 is already lipidated to 
the outer membrane of the apicoplast (64). It is difficult to imagine how Atg8 is lipidated 
without an activating and conjugating enzyme, other than the possibility that an E1 and 
E2 enzyme function has divergently evolved. Further localization studies in other stages 






 Teasing apart how autophagy can promote cell survival and cell death has been a 
central question for all eukaryotes and is especially important in cancer research. 
Autophagy may well be the mechanism by which the malaria parasite dies with CQ and 
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artemisinin treatment, necessitating a better understanding of PCD pathways in 
Plasmodium as well.   
 It appears that Atg8, due to its unique ability to be covalently attached to 
membranes and to bind diverse proteins through adaptors has been conserved throughout 
Eukarya, even when other autophagy proteins are not. The list of non-autophagic 
functions for Atg8 homologues continues to grow and includes functions independent of 
membrane conjugation (96, 97). Since P. yoelli Atg8 knockouts are nonviable and 
conditional knockouts are difficult in Plasmodium, a selective inhibitor preventing 
lipidation of Atg8 would be an invaluable tool that could also serve as a potential 
antimalarial therapeutic. Plasmodial Atg8’s essentiality and our recently elucidated 
crystal structure, presented in Chapter 2, make PfAtg8 a prime target for structure-based 
drug design (45). Our efforts to this end are presented in Chapter 3. Finally, we present 
intriguing data on the function of Atg8 in Plasmodium in Chapter 4. 
 
 20
Methods & Materials 
 
Bioinformatics search: The genome sequence of P. falciparum was published in 2002 
and is stored along with various data associated with each gene in the Plasmodium 
Genome database (PlasmoDB) (98, 99). The amino acid coding sequence of 
Saccharomyces cerevisiae and Homo sapien ATG genes were queried for putative 
homologues using the WU-BLAST program within PlasmoDB. Hits were identified 
based on the Expect (e)-value of the BLAST search, as well as annotation in PlasmoDB, 
any functional knowledge, conservation among all the plasmodial species sequenced, and 
the length of the hit in comparison to the query. Of note, the most likely homologue did 
not necessarily have the highest e-value in the initial PlasmoDB BLAST search. 
Additionally the species used as the query had a major impact on the returned BLAST 
hits. Often the same hit was identified with both the human and yeast homologue query 
but sometimes a strong hit was only identified with one species. In a few cases other 
species were used as a query (Table A.2). An inverse BLAST was performed with the 
potential hits using NCBI Position-Specific Iterated (PSI) BLAST against the S. 
cerevisiae or H. sapiens non-redundant protein sequence database, and if that failed, with 
the Domain Enhanced Lookup Time Accelerated (DELTA) BLAST. Hits were 
additionally screened in Pfam to see if they contained the domains or motifs important to 
that homologue’s function, such as coiled-coil domains and lipid binding motifs. For 
transmembrane proteins, the TMHMM server 2.0 



















Figure 1.2. Atg8 conjugation pathway. A. Overview of macroautophagy and localization of Atg8 to 
growing autophagosome. B. Yeast Atg8 conjugation pathway. 1. Atg8 is attached to 
phosphatidylethanolamine in the phagophore through a ubiquitin-like conjugation cascade. Atg8 leads to 
autophagosome elongation and maturation. The autophagosome fuses with the vacuole to degrade its 
contents. 2. Atg4 reverses the covalent attachment, recycling Atg8 from the outer membrane before 
degradation in the vacuole. C. Putative Atg8 conjugation pathway in Plasmodium. Red line indicates the 









Figure 1.3. Conservation of autophagy proteins in Plasmodium. Proteins essential for macroautophagy 
are depicted as rectangles. Ovals represent proteins whose essentiality is not known. Black indicates strong 
evidence for homology (e-value less than 1e-10 in initial BLAST within PlasmoDB and reciprocal 
identification using PSI-BLAST with e-value less than 1e-20). Gray indicates homology less clear (initial 
e-value cutoff of 0.012 and identification of initial query in either PSI- or DELTA-BLAST with e-value 
that may not be significant). White indicates no orthologue identified. *Human proteins FIP200 and 











Figure 1.4. Expression data of autophagy proteins during Plasmodium life cycle. RNA-Seq and mass 
spectrometry data from PlasmoDB and data from published studies is compiled. All data is for P. 
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 The autophagy-related proteins are thought to serve multiple functions in 
Plasmodium and are considered essential to parasite survival and development. We have 
studied two key interacting proteins, Atg8 and Atg3, of the autophagy pathway in P. 
falciparum. These proteins are vital for the formation and elongation of the 
autophagosome and essential to the process of macroautophagy. Autophagy may be 
required for conversion of the sporozoite into erythrocytic-infective merozoites and may 
be crucial for other functions during asexual blood stages. Here we describe the 
identification of an Atg8 family interacting motif (AIM) in Plasmodium Atg3, which 
binds PfAtg8. We determined the co-crystal structure of PfAtg8 with a short Atg3103-110 
peptide, corresponding to this motif, to 2.2 Å resolution. Our in vitro interaction studies 
are in agreement with our X-ray crystal structure. Furthermore they suggest an important 
role for a unique Apicomplexan loop absent from human Atg8 homologues. Together our 
structural and interaction studies represent a starting point for future antimalarial drug 







 Atg8 is a conserved Ub protein, necessary for macroautophagy as well as many 
types of selective autophagy. In all structures determined, Atg8 homologues contain a Ub 
fold at its core with N-terminal helix extensions. Atg8 is also similar to Ub in its 
utilization of a conjugation pathway for covalent attachment to its substrate. Whereas Ub, 
SUMO, and other Ub-like proteins are covalently attached to other proteins, Atg8 is 
unique in its attachment to a lipid head group, phosphatidylethanolamine (PE) and 
possibly also phosphatidylserine (PS) (100).  
 Most Atg8 orthologues require proteolytic processing of one or several amino 
acids to expose a C-terminal glycine. The exposed C-terminus of Atg8 is attached to its 
E1 activating enzyme, Atg7, through a thioester bond that requires activation by ATP 
hydrolysis. Atg8 is then transferred to its E2 conjugating enzyme, Atg3, to form another 
thioester bond before being transferred to PE in the phagophore membrane (Figure 1.2B). 
In addition to thioester formation with Atg3, Atg8 interacts noncovalently with Atg3 
prior to substrate attachment (101). In vitro, Atg8 lipidation is accelerated through the 
E3-like action of the Atg12-Atg5 conjugate (33). It is not known if a functional E3 exists 
in Plasmodium as putative orthologues have only been identified for a portion of the 
machinery (102). Additionally, Plasmodium Atg8 is synthesized with a C-terminal 
glycine, indicating that Atg4 would not be necessary for activation (68). However, a 
likely Atg4 homologue is present in Plasmodium and is thought to regulate Atg8 
localization by releasing Atg8 from membranes as is seen in other species (Figure 1.2C).  
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 Lipidation of Atg8 to the autophagosome instills Atg8 with unique features within 
the autophagy pathway. Atg8 serves as the canonical autophagy marker as it forms a 
stable interaction with the autophagosome early and remains associated through 
lysosome-autophagosome fusion and subsequent degradation (70) (Figure 1.2A). 
Autophagy also serves to recruit substrates into the autophagosome for selective 
autophagy through interaction with intermediary autophagic cargo receptors (reviewed in 
(103)). These receptors, like Atg3, interact with Atg8 through their Atg8-interacting 
motif (101).  
 Here we report x-ray crystal structure of PfAtg8 with a peptide corresponding to 
PfAtg3. We provide biochemical and structural evidence that P. falciparum (Pf) Atg8 
binds PfAtg3 in a conserved mechanism as reported in other species, including humans. 
Despite this conservation we have discerned regions in the parasite protein that can be 






Verification of PfAtg8 and PfAtg3 interaction   
 Recombinant Plasmodium Atg8 (PF3D7_1019900) expressed in E. coli showed 
very low solubility in all species tested (PbAtg8, PvAtg8, and PfAtg8). While mutation of 
Lys26 to Pro in yeast Atg8 decreased aggregation and retained full autophagic activity 
(104, 105), Proline is already present at this position in Plasmodium. Through site-
directed mutagenesis and thermal shift assays (TSAs), a triple cysteine mutant (C37I, 
C119S, C122S) was identified that had significantly increased solubility and is referred to 
here as the cysteine mutant (CM) (Figure 2.1). Because Cys37 was predicted with 
homology modeling to be buried within the Ub-like core, we mutated this residue to the 
hydrophobic amino acid, Ile. Exposed free Cysteine residues are often a source of 
aggregation and in otherwise refractory proteins, mutagenesis has been successful in 
yielding crystals (106). Similar procedures to decrease aggregation, such as cysteine 
carboxymethylation, were not found to alter the overall protein structure when compared 
to the native protein structure (107).  
 We also cloned and expressed the putative E2 conjugating enzyme, PfAtg3, in E. 
coli. Notably, amplification of blood stage strain 3D7 cDNA yielded a product matching 
the PF3D7_0905700.2 variant of Atg3 from the PlasmoDB database. Binding of PfAtg8 
to PfAtg3 was tested through various methods, including native electromobility gel shift 
assays and dynamic light scattering (DLS) (Figure 2.2). Isothermal titration calorimetry 
(ITC) provided a dissociation constant (KD) of 406 nM for the interaction and a one-to-
one binding stoichiometry, in agreement with the DLS results (Figure 2.2). Surface 
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plasmon resonance (SPR) kinetic experiments showed a similar affinity for PfAtg3 to 
either wild type (WT) or CM PfAtg8 (Figure 2.3), validating our use of PfAtg8CM in 
biochemical and structural studies. We next sought to elucidate the interaction interface 
on each protein.  
 
Molecular Basis of Plasmodium Atg8-Atg3 Interaction   
 An Atg8 family interacting motif (AIM) has been identified in Atg8’s conjugating 
enzyme, Atg3 as well as in Atg8-binding proteins involved in the cytoplasm-to-vacuole 
targeting (Cvt) pathway in yeast and selective autophagy in mammals. The motif is 
!XX", where ! is aromatic and " is hydrophobic, with nearby acidic residues preferred 
(108-110). We identified two potential AIMs in PfAtg3, shown in Figure 2.4, and 
mutated the Trp105 and Trp214 in each to Alanine. PfAtg3 was recombinantly expressed 
with a maltose binding protein (MBP) tag and binding to PfAtg8 was tested through MBP 
pulldown assays. PfAtg8 binding was unaffected in the PfAtg3W214A mutant and 
decreased by 35% in PfAtg3W105A as compared to wild type (Figure 2.4A). TSAs 
confirmed the decreased binding in the W105A mutant is not due to destabilization of the 
tertiary structure and implicates this region as a potential AIM (Figure 2.4B). 
 We next tested whether a synthetic peptide, corresponding to residues 103-110 of 
the potential AIM were sufficient for binding PfAtg8. The PfAtg3103-110 peptide led to a 
concentration-dependent positive shift in the Tm of PfAtg8 in TSAs, indicating binding 
and stabilization of PfAtg8, while a control peptide of PfAldolase364-369 did not affect the 
Tm (Figure 2.5). To exclude nonspecific stabilization by the peptide, we evaluated 
whether the PfAtg3103-110 peptide could compete with full length PfAtg3 for PfAtg8 
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binding in SPR studies. PfAtg8 was injected over a chip containing immobilized MBP-
PfAtg3 with increasing concentrations of PfAtg3103-110 or PfAldolase364-369 peptides and 
the SPR response was measured. The PfAtg3103-110 peptide inhibited interaction with full 
length PfAtg3 in a concentration-dependent manner, whereas the control peptide did not 
have an effect (Figure 2.5), supporting the identification of a conserved AIM in PfAtg3, 
WLLP, responsible for PfAtg8 binding. 
  
Crystallization of PfAtg8CM-PfAtg3103-110complex 
 Protein crystals of PfAtg8CM were obtained in the presence of the PfAtg3103-110 
peptide, presented in Figure 2.6A,B. The structure of the complex was solved by 
molecular replacement with an ensemble of 20 models using Phaser as described in the 
materials and methods section (111). The structure was refined to an Rwork/Rfree 
combination of 20.5/27.9% with a twin fraction of 9.4% and zero Ramachandran outliers 
(Table 2.1). The asymmetric unit contained three copies of Atg8 and three copies of the 
bound peptide corresponding to a 1:1 ratio of protein to peptide. The buried surface area 
between any two given chains of PfAtg8 is approximately 1,330 Å2, not indicative of a 
stable multimer in solution. The three copies of PfAtg8 superimpose with an r.m.s.d. of 
0.02 Å for 120 C!-atoms. The PfAtg3103-110 peptide also superimposes well except for the 
N- and C-terminal residues, which adopt different orientations in the crystal lattice. 
PfAtg8 contains an N-terminal domain composed of two alpha helices attached and 
stabilized via hydrogen bonding to a C-terminal ubiquitin (Ub)-like domain as has been 
visualized in other Atg8 homologues (108, 112-114). Our structure additionally contains 
two short beta strands, connected by a beta turn between !3 and "5 which is absent from 
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all other homologue structures (Fig. 2.7A). Sequence alignment shows that Plasmodium 
Atg8 contains an insertion of nine residues only conserved within Apicomplexa (Figure 
2.7B), which we term the A-loop. These residues comprise !3 and the turn in the loop. !3 
forms numerous hydrogen bonds with the antiparallel !4 strand. The secondary structure 
observed for !3 and !4 may be due to crystal contacts as the loop forms numerous 
hydrogen bonds with the PfAtg3103-110 peptide of another chain and may explain why we 
were unable to obtain crystals without the peptide (Figure 2.7C). We term the pocket 
formed between A-loop and the Ub core the A-loop pocket.  
 
The cargo-receptor site 
 In yeast and mammals two hydrophobic pockets, termed the cargo receptor site, 
bind AIMs in diverse proteins. The “W-site” binds Trp and the “L-site” binds Leu in the 
AIM (101, 108, 115) (109, 116). Our crystal structure confirmed that two hydrophobic 
pockets in PfAtg8 are responsible for binding the PfAtg3103-110 peptide (Figure 2.8A). 
This is similar to the determined structures of Atg8-Atg19peptide and microtubule-
associated protein 1 light chain 3 (LC3)-p62peptide structures (108, 115). The side chain of 
PfAtg3 Trp105 binds deeply inside the W-site of PfAtg8, which consists of residues L4, 
E16, T17, I20, P29, V30, V31, K47, F48, L49, and Y112. Pro108 of the PfAtg3 peptide 
fits in the L-site, consisting of residues R27, F48, L49, V50, P51, M54, E58, F59, I62 and 
M99 (Figure 2.8B). The peptide additionally makes hydrogen bonds with the side chains 
of K45, E58, and H66 surrounding the W- and L-site.  
 
Identification of Atg3-interacting residues 
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 We next sought to identify the residues of PfAtg8 involved in binding PfAtg3. To 
verify that the W- and L-site pockets binds PfAtg3 in solution, the following mutants 
were made in and near the potential cargo receptor site: K47E, L49A, R27E, 
K47E/K19E, E44A/K45S/K46A, shown in Figure 2.9A. Our structure elucidated a loop 
of nine amino acids (68 to 76) located below the W/L-sites. Sequence alignment shows 
that these residues are conserved only within Apicomplexa (Figure 2.7B). As loops are 
often important for imparting specificity, we deleted residues 68-76. PfAtg8 variants 
were tested for binding using an MBP pulldown assay with immobilized MBP-PfAtg3 as 
before (Figure 2.9C). R27E, K47E, and L49A W-site mutations all reduced binding to 
MBP-PfAtg3. Binding was not reduced to the same degree in the L49A mutant as in the 
yeast system.  The triple mutant PfAtg8E44A/K45S/K46A, containing mutations near the W-
site showed moderate decreases in binding. Strikingly, PfAtg868-76! binding was reduced 
by 80%, as quantified with ImageJ (117), suggesting a large interaction surface between 
PfAtg8 and PfAtg3. Thermal shift assays verified that, with the exception of R27E, the 
mutations were not structurally destabilizing (Figure 2.9D) (118). Our studies confirm 
that the cargo receptor site is conserved in PfAtg8 and is involved in binding PfAtg3. 
 
Comparison of PfAtg8 to human Atg8 homologues 
 The overall conservation of the binding site makes it a challenging task to design 
specific inhibitors targeting Plasmodium, however differences exist in amino acid 
composition (Figure 2.8), electrostatic surface potential and cargo receptor pocket size. 
For example, the W-site of Plasmodium is ~100 Å3 larger than the corresponding site in 
the human orthologues, microtubule-associated protein 1 light chain 3 (LC3), and Golgi-
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associated ATPase enhancer of 16 kDa (GATE-16). Figure 2.10 compares the 
electrostatic surface on the Atg3-binding face of PfAtg8 with GATE-16 and LC3. All 
three proteins have a prominent positively charged band on the cargo receptor site face. 
Relative to PfAtg8, the orientation of this band is tilted 40 and 55 in GATE-16 and 
LC3, respectively.  Both PfAtg8 and GATE-16 show striking differences compared to 
LC3, where the positive charge is concentrated around the central area of the protein and 
!1 and !2 form an acidic patch above the W-site that is basic in the other proteins. The L-
site of GATE-16 is predominately positively charged whereas PfAtg8 is more neutral in 
this region. An acidic patch formed between !3 and the loop between "1 and "2 in both 
GATE-16 and LC3 is basic and neutral in our structure and forms a deeper groove due to 
the "3 strand inserted in the PfAtg8 structure.  
 These differences led us to hypothesize that the human Atg8 homologues would 
not bind Plasmodium Atg3. We compared binding of recombinant human LC3 and 
PfAtg8 to immobilized PfAtg3 with SPR-based assays. Whereas PfAtg8 bound PfAtg3 
with a dissociation constant of 296 nM, LC3 did not bind PfAtg3 (Figure 2.11), 





Our biochemical and structural studies indicate that PfAtg8 binds an AIM in 
PfAtg3. To date, the crystal structure of Atg3 has only been elucidated for yeast and 
Arabidopsis thaliana (PDB codes 4GSL, 3VX8, 2DYT, 3T7G). Biochemical analysis of 
yeast Atg3 indicates it interacts with the W- and L-site of Atg8 through an AIM located 
in the handle region of Atg3 (109). The handle region is severely truncated in 
Plasmodium Atg3, similarly as in the human homologue (Figure 2.12). Additionally, the 
PfAtg3 AIM differs from known motifs in yeast and humans by the presence of proline, 
rather than leucine or isoleucine at the fourth position of the motif (!XX"). Prolines are 
often found at the edges of beta-strands suggesting the possibility this region forms a beta 
strand in solution. Recent NMR and X-ray studies on yeast Atg7 and Atg8 suggest that 
substrates can bind the Atg8 cargo receptor site without forming an intermolecular beta 
sheet (119). Crystallization of full length Plasmodium Atg3 will help elucidate the 
secondary structure of the AIM while solution NMR experiments may reveal the different 
states of this region in the presence or absence of a substrate.  
 PfAtg8 shows the greatest sequence and structural similarity, with minimal 
r.m.s.d., to GATE-16, implicated in intra-Golgi trafficking and macroautophagy in 
mammals. Like GATE-16, it does not contain the extra beta strand located between #3 
and $4 in LC3 and TbAtg8. Considering the 74% sequence similarity between the cargo 
receptor site of the human homologue LC3 and Plasmodium Atg8, it is surprising that 
LC3 cannot interact with PfAtg3. However, differences in the extent and orientation of 
charges, as well as the larger size of the pocket in PfAtg8 may explain the lack of binding 
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in the heterologous system. These charge and size differences can be exploited to 
selectively target the parasite autophagy system. Additionally, our structure contains a 
semi-ordered insertion of two beta strands between !3 and "5 with respect to structures in 
other species. Our mutagenesis studies suggest an important role for the Apicomplexan-
specific loop (A-loop) in mediating interactions between PfAtg8 and PfAtg3. Together 
our structural and biochemical studies implicate a unique pocket formed between the loop 
and the Ub-like core, which could potentially be targeted with a small molecule inhibitor. 
Further studies are required to determine how this region interacts with PfAtg3 and if it is 
amenable to drug design. While the cargo receptor site is well conserved across Atg8 
homologues, there is more divergence on the other side of the protein, as well as regions 
just outside the receptor site including !1, which may be able to serve as anchoring points 
during drug design (Figure 2.13).   
  
Future Directions:  
 Because the A-loop is specific to Apicomplexa, understanding how these residues 
bind PfAtg3 would help guide drug design. While Toxoplasma gondii (Tg)Atg8 
expresses and purifies well, TgAtg3 showed low expression. We have created new 
constructs to test for improved expression. In the future we will attempt to co-crystallize 
the Atg8-Atg3 complexes from Toxoplasma and other Apicomplexa. Construct 
engineering was successful in producing a more stable Atg8 protein for crystallization. 
We could undertake similar strategies such as surface entropy reduction, cysteine 
mutation or methylation, or truncations with PfAtg3.                                                                           
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Methods & Materials 
 
Cloning, expression, and purification: Unless otherwise stated, purification steps were 
conducted on ice or at 4°C. The purity of protein purification samples was assessed with 
SDS-PAGE, visualized with either Gelcode blue (Thermo Scientific) or coomassie stain.   
 
Cloning, expression, and purification of PfAtg3: PfAtg3 was cloned from P. 
falciparum 3D7 cDNA using primers containing either a His6 tag and NcoI and BamHI 
restriction sites (A3HF and A3R (Table A.2 and A.3)), ligated into a pET45b vector or 
just NcoI and BamHI sites (A3MF and A3R (Table A.2 and A.3) ligated into a modified 
pET45b vector to have an N-terminal MBP tag followed by a TEV protease cleavage site 
(MBP-PfAtg3). Constructs were verified with DNA sequencing and transformed into E. 
coli BL21-RII cells. A single colony was used to inoculate TB-media and grown at 37°C. 
Protein expression was induced at an OD600=03.5 with 1 mM IPTG and expressed at 
20°C for 16 hrs. Cells were harvested and the bacterial pellet resuspended in lysis buffer 
containing 50 mM Tris pH 7.0, 500 mM NaCl, with a Complete EDTA-free protease 
inhibitor cocktail tablet (Roche) and benzonase (Sigma). Cells were lysed with an 
EmulsiFlex C5 cell disruptor at 15,000 PSI and cleared with 35,000 x g for 35 min. 
MBP-PfAtg3 was applied to amylose resin and washed with lysis buffer. Bound protein 
was eluted in 50 mM Tris pH 7.0, 2 mM DTT, 20 mM maltose. His6-PfAtg3 was purified 
with TALON™ resin (Clonetech). Following a washing step with lysis buffer, PfAtg3 
was eluted in 50 mM Tris pH 7.0, 300 mM imidazole. Constructs were further purified 
using anion exchange chromatography over a RESOURCE™ Q column (GE Healthcare) 
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with a gradient of 0 to 1 M NaCl in 50 mM Tris pH 7.0, 2 mM DTT using an ÄKTA 
purifier system. 
 
Cloning, Expression, and Purification of PfAtg8: PfAtg8 amplified from 3D7 cDNA 
and ligated into a PQE-30 vector (Qiagen) was kindly provided by Dr. I. Coppens, Johns 
Hopkins University, USA. PfAtg8 was sub-cloned using primers A8MF and A8R (Table 
A.2 and A.3), containing NcoI and BamHI restriction sites, and ligated into a modified 
pRSF-1b vector with an N-terminal Maltose binding protein (MBP) tag and Tobacco etch 
virus (TEV) protease cleavage site. An N-terminal His6-tagged construct was made using 
primers A8HF and A8R, containing NcoI and BamHI sites and hexahistidine tag, and 
ligated into a pRSF-1b vector (Novagen). Plasmids were transformed into E. coli BL21-
RII cells containing a rare codon plasmid. A single colony was used to inoculate TB 
media containing 50 µg/mL kanamycin and 34 µg/mL chloramphenicol and grown at 
37°C. At an O.D. 600 of 3.3, protein expression was induced with 0.3 mM IPTG and 
grown for 16 h at 20°C under vigorous shaking.  
 Cells were harvested by centrifugation at 4,000 x g, 30 min, resuspended in 50 
mM HEPES pH 8.0, 500 mM NaCl, 1 mM MgCl2, 10% glycerol, a tablet of Complete 
EDTA-free protease inhibitor cocktail tablet (Roche) and 500 U benzonase, and lysed 
using an EmulsiFlex C5 cell disruptor at 15,000 PSI. After centrifugation at 35,000 x g 
for 30 min, MBP-PfAtg8 lysate was incubated with amylose resin (NEB) and washed 
with lysis buffer before eluting with 50 mM HEPES pH 8.0, 20 mM maltose, 10% 
glycerol. Protein was dialyzed with homemade MBP-TEV protease at molar ratio of 
1:100 in 50 mM MES pH 6.5, 10% glycerol, 0.5 mM EDTA, 1 mM DTT. Cleaved 
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protein was separated from TEV and MBP through cation exchange over a 
RESOURCE™ S column (GE Healthcare) using an ÄKTA purifier system. Pure 
fractions were dialyzed in 50 mM MES pH 6.5, 50 mM NaCl, 10% glycerol overnight 
and concentrated using a filter device with 3 kDa MWCO (Amicon).  
 After centrifugation, His6-PfAtg8 lysate was incubated with Cobalt-charged 
TALON resin (Clonetech), washed with lysis buffer, and eluted in 50 mM HEPES pH 
8.0, 300 mM imidazole, 10% glycerol. Elutions were further purified with a 
RESOURCE™ S column as for MBP-PfAtg8.  
 
Expression and Purification of hLC3: MAP1LC3B (hLC3) was amplified from a 
mammalian expression vector (generous gift of Dr. M. Hardwick, Johns Hopkins 
University) and ligated into a modified pET45b vector to contain an MBP N-terminal tag 
and TEV protease cleavage site using primers L3MF and L3MR containing NcoI and 
BamHI restriction sites (Table A.2 and A.3). MBP-LC3 was expressed and purified 
following the same protocol as MBP-PfAtg8.  
 
Site-directed mutagenesis: Amino acid changes were introduced into constructs using 
the protocol and reagents in the QuickChange® Lightning site-directed mutagenesis kit 
(Agilent) (Table A.2 for primers, A.3 for constructs). A previously published, modified 
protocol was followed to delete residues 68-76 from PfAtg8 (120).   
 
Native Electromobility Shift Assay (EMSA): His6-PfAtg8 and His6-PfAtg3 in 50 mM 
HEPES pH 8, 300 mM Imidazole, 10% glycerol, 1 mM MgCl2, 10 mM DTT were mixed 
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in equimolar amounts and run in native loading buffer on a Tris-HCl 7.5% gel (Biorad) at 
4°C, 80V for 4.5 hrs and visualized with Gelcode blue protein stain (Thermo Scientific).  
Proteins were also run alone at the same concentration for comparison.  
 
Isothermal titration calorimetry: Binding affinities and thermodynamic binding 
parameters for His6-PfAtg8 and His6-PfAtg3 were determined using a MicroCal VP-ITC 
instrument (GE Healthcare). His6-PfAtg3 at 97.8 µM was titrated into cell containing 17 
µM of His6-PfAtg8 in 50 mM HEPES pH 7.0, 50 mM NaCl, 10% glycerol, 1 mM TCEP 
at 25°C. An initial injection of 3 µL was followed by 28 10 µL injections, 20 sec. each 
with 400 sec. spacing, a filter period of 2 and stirring speed of 500 rpm. Data analysis 
was performed with Origin 7 software using the heats of dilution of the titrant to 
normalize the raw heats of injection and a single site-binding model.  
 
SPR: Runs conducted on a Biacore 3000 instrument (GE Healthcare). Unless otherwise 
stated, runs were conducted in running buffer (RB1) containing 354 µM KH2PO4, 1.87 
mM Na2HPO4, 51.5 mM NaCl, pH 7.4, 0.01% v/v P20, 0.2 mg/ml BSA at 25C (Quality 
Biologicals). Bound analyte was dissociated from the chip using 1 injection of 1 M 
MgCl2 followed by 2 blank injections of RB between each concentration. Binding and 
equilibrium constants were determined with Scrubber (BioLogic™). A double 
referencing method was applied to correct for nonspecific binding to the chip with 
interspersed blank injections correcting for baseline drifts.  
 PfAtg3 immobilization: The surface chip was pre-conditioned with multiple 
injections of 20 mM glycine pH 2.2 prior to pH scouting for identification of optimal 
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conditions for Atg3 binding to the sensor chip. MBP-PfAtg3, dissolved in 10 mM Na 
Acetate pH 4.0, was immobilized by amine coupling to the surface of a CM3 sensor chip 
(GE Healthcare). 
 Determination of dissociation constants for PfAtg8 WT and CM: His6-PfAtg8CM 
and His6-PfAtg8WT were injected over MBP-PfAtg3-immobilized CM3 chip at 20 
µL/min with 6 2-fold dilutions at the lowest concentration, increasing to 250 nM. 
Injection volumes were 40 µL and 60 µL and dissociation times were 120 sec and 150 
sec, for CM and WT, respectively. 
 Inhibition of PfAtg8-PfAtg3 interaction by PfAtg3103-110 peptides: A dilution series 
was set up with His6-PfAtg8CM at a constant concentration of 200 nM and 9 3-fold 
dilutions of peptide starting at 400 µM in RB. His6-PfAtg8CM without peptide injections 
were interspersed to check for chip decay or decreases in protein activity. Each 
concentration was run in triplicate at 20 µL/min, with 60 µL injections and a 150 sec 
dissociation time. 
 Binding analysis of PfAtg8CM and hLC3: Binding was measured using purified 
His6-PfAtg8CM and hLC3 with 7 2-fold dilutions in 1.06 mM KH2PO4, 5.6 mM 
Na2HPO4, 154 mM NaCl, pH 7.4, 0.01% v/v P20, 0.2 mg/mL BSA (RB2) starting at 625 
nM injected at 40 µL/min at 37°C.  
 
Crystallization of PfAtg8CM-PfAtg3103-110: MBP-PfAtg8CM was expressed and purified 
as specified. Pure fractions from the RESOURCE™ S column were further purified on a 
HiLoad S75 column (GE Healthcare) in 50 mM MES pH 6.5, 7% glycerol, 1 mM MgCl2, 
2 mM DTT. Equimolar PfAtg3103-110 peptide was added to PfAtg8CM at 2 mg/ml and 
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concentrated in a 3 kDa MWCO filter device (Amicon) to 8 mg/mL. More peptide was 
added to a final concentration of 2.5 mM. Original crystals were identified from a screen 
set up with 200 nL of protein and 200 nl reservoir using a Mosquito crystallization robot 
(TTP Labtech) containing 100 mM MES pH 6, 0.2 M Ca(OAc)2, 20% w/v PEG 8000 
equilibrated at 20°C in a 96-well sitting drop INTELLI-PLATE® (Art Robbins 
Instruments). Conditions were further optimized to obtain larger crystals using a 24-4 
sitting drop INTELLI-PLATE® (Art Robbins) with reservoir containing 100 mM MES 
pH 6.5, 100 mM Ca(OAc)2, 20% w/v PEG 8000 and sitting drops containing 2 µL protein 
at 8 mg/mL and 2 µL reservoir, equilibrated at 20°C. Crystals were mounted in a 0.3 mm 
nylon cryoloop (Hampton Research) and flash frozen directly in liquid nitrogen before 
shipping to the Stanford Synchrotron Radiation Lightsource. Data sets were collected at 
SSRL beamline 12-2 at ! 1.033 Å using a microfocus beam of 6 x 9 µm and the Berkeley 
Advanced Light Source beamline 5-01 at ! 0.977 Å with a 100x100 µm beam.  
 
Data Collection and Structure Determination: The crystals belonged to the space 
group P21 with cell dimensions of a=33.30 Å, b=111.08 Å, c=57.09 Å and "=92.58. 
Data reduction and scaling was carried out with XDS/XSCALE (121). The refined twin 
fraction was 9.6% as determined by Refmac (122). The asymmetric unit contained three 
monomers resulting in a solvent content of 48%. We initially failed to obtain a molecular 
replacement solution with various models using Phaser (111), MOLREP (123), and 
BALBES (124).  Only the combination of 20 models including homology models 
generated by Robetta (125) yielded a molecular replacement solution using 
phenix.ensembler (126) together with phenix.automr (111). Manual rebuilding and 
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refinement was carried out in Coot (127). TLS refinement was performed with TLS 
groups determined by the TLSMD server (128) using Phenix (129, 130). PfAtg8 was 
refined to a crystallographic Rwork of 20.5% and an Rfree of 27.9% (131). The final 
structure was analyzed with validation tools in Coot (127) as well as MOLPROBITY 





Table 2.1. Data collection, phasing and refinement statistics 
 Native 
Data collection SSRL12-2 ALS5-01 
Space group P21 P21 
Cell dimensions     
    a, b, c (Å) 33.30, 111.08, 57.09 33.26, 110.33, 56.57 
!,",# () 90, 92.58, 90 90, 92.49, 90 
Wavelength 1.0332 0.9774 
Resolution (Å) 31 - 2.2 (2.24-2.18) 20 - 2.25 (2.3-2.25) 
Rmerge  21.5 (91.8) 10.1 (44.7) 
I / $I 7.3 (1.6) 9.05 (2.2) 
Completeness (%) 87.6 (45.0) 88.2 (46.2) 
Redundancy 2.1 (2.2) 1.13 (1.54) 
Wilson B (A2) 29.08 23.94 
Beam size (µm) 6 x 9 100 x 100 
   
Refinement   
Resolution (Å) 31 – 2.2  20 – 2.2 
No. reflections 21538 15705 




No. atoms   
    Protein 3289 3289 
    Ligand/ion 23 23 
    Water 331 331 
B-factors (Å2)   
    Protein 31.6 19.2 
    Ligand/ion 51.4 57.6 
    Water 46.2 54.77 
R.m.s deviations   
    Bond lengths (Å) 0.008 0.012 
    Bond angles (°) 1.197 1.306 
Ramachandran main chain dihedral analysis**   
favored 96.9% (370/382) 97.1% (371/382) 
allowed 3.1% (12/382) 2.9% (11/382) 
outliers 0 0 
Molprobity side chain rotamer analysis**  
bad rotamers 1.3% (5/372) 0.81 (3/372) 
*Highest resolution shell is shown in parentheses.  














Figure 2.1. Thermal stability of PfAtg8 Cysteine mutant. Wild type (WT) and cysteine mutant (CM) 
His6-PfAtg8 were expressed and purified concurrently and tested for thermal stability. A. Melting curve of 
PfAtg8 for CM (blue) and WT (black). B. The melting temperature of WT and CM was determined from 
the first derivative melting curve and plotted for three internal measurements. Error bars represent standard 








Figure 2.2. Protein interaction studies of recombinant PfAtg8 and PfAtg3. A. Native electromobility 
shift assay. His6-PfAtg8 and His6-PfAtg3 were run alone and together on a native PAGE and stained with 
Gelcode blue. B. Dynamic light scattering analysis of His6-PfAtg8, His6-PfAtg3, and the complex with the 
radius and predicted MW for a globular protein. C. Isothermal titration calorimetry analysis of His6-PfAtg3 
injected into cell containing His6-PfAtg8. The stoichiometry of binding was determined to be one-to-one 









Figure 2.3. Comparison of PfAtg8 WT and CM binding to PfAtg3 with SPR-based Biacore studies. 
MBP-PfAtg3 was immobilized on a CM3 chip and His6-PfAtg8 variants were injected at six 2-fold serial 
dilutions in triplicate. Sensorgram shows response units over time of run. Orange lines indicate fit used by 
Scrubber data processing software (BiologicTM Software) to derive kinetics and dissociation constant, 









Figure 2.4. Identification of a putative AIM in PfAtg3. A. Alignment of known AIMs in other species 
with potential AIMs in PfAtg3. Aromatic residues at position 1 are denoted in green, hydrophobic residues 
at position 4 in blue, and acidic residues in red. B. In vitro MBP pulldown assay. His6-PfAtg8CM was co-
expressed with MBP-PfAtg3 variants and purified with an amylose affinity column. Left: Bound proteins 
were subjected to SDS-PAGE and visualized with coomassie stain. Gel represents one of three independent 
experiments. Right: Binding was quantified with ImageJ as the ratio of PfAtg8 to PfAtg3, normalized to 
WT binding levels. Error bars represent means and standard deviation (SD) from three independent 
experiments. C. Thermal shift assay of His6-PfAtg3 WT and W105A mutant. Error bars represent means 









Figure 2.5. Identification of a PfAtg3 peptide that binds PfAtg8. A. TSA with peptides. His6-PfAtg8CM 
was incubated with increasing concentrations of PfAtg3 and PfAldolase peptides and fluorescence of 
SYPRO® orange dye was measured from 20-80°C over 60 min. B. SPR competitive binding assay. His6-
PfAtg8CM was injected over an MBP-PfAtg3-conjugated chip with increasing concentrations of PfAtg3103-













Figure 2.6. Overall structure of PfAtg8CM-PfAtg3103–110. A. The overall structure of PfAtg8CM is shown 
as a cartoon representation with the PfAtg3-peptide as a stick model. Beta sheets are colored yellow and 
alpha helices colored red. B. Electron density corresponding to PfAtg3103–110 peptide is shown bound to 
cargo receptor site of PfAtg8. 2Fo-Fc map electron density for peptide is shown in blue at 1!. Fo-Fc 






Figure 2.7. Identification of an Apicomplexan-specific loop in PfAtg8. A. Superposition of structures of 
Atg8 homologues (PDB code in paratheses) from Saccharomyces cerevisiae (2DYT), Homo sapiens 
(1GNU, 3ECI), Bos Taurus (1EO6), Rattus norvegicus (1UGM, 1KJT), Bombyx mori (3M95), and 
Trypanosoma brucei (3H9D) represented as ribbons. PfAtg8 is shown in lime green, with arrow 
highlighting loop absent in other structures. B. Multiple structural sequence alignment of Apicomplexa, 
human, and yeast Atg8 homologues. Plasmodial Atg8 homologues were aligned with H. sapiens LC3 and 
S. cerevisiae Atg8 using 3D-Coffee (www.tcoffee.org) (PDB codes 1EOY, 2ZJD, and 2ZPN, respectively) 
and visualized with ESPript (http://espript.ibcp.fr/ESPript/). Structural elements shown above sequence are 
based on the PfAtg8 crystal structure. Loop region unique to Apicomplexa is highlighted in yellow. C. 
Crystal contacts between neighbor PfAtg8 molecules mediated by PfAtg3-peptide. Inset shows PfAtg3 
peptide (cyan) hydrogen bond network with PfAtg8 A-loop residues in the nearest symmetry mate (red) as 






Figure 2.8. Analysis of the cargo receptor site of PfAtg8. A. The overall structure of PfAtg8 is displayed 
as a cartoon with the cargo receptor site as surface representation. The PfAtg3-peptide is shown in cyan. 
Residues are color-coded depending on presence in the human homologue, GATE-16; yellow = identical, 
orange = similar, red = different. B. Close-up of cargo receptor site. Residues composing the W- and L-




Figure 2.9. Identification of Atg3-interacting residues in PfAtg8. A. PfAtg8 mutations color-coded on 
the crystal structure. B. In vitro MBP pulldown assay. Immobilized MBP-PfAtg3 was incubated with His6-
PfAtg8 mutants. Bound proteins were subjected to SDS-PAGE. Asterisk denotes MBP-PfAtg3 and plus 
sign denotes His6-PfAtg8. Gel is representative of three experiments. Bottom: Binding was quantified with 
as the ratio of bound PfAtg8 to PfAtg3, normalized to WT levels. Bars represent the mean and SD of three 












Figure 2.10. Electrostatic surface potential of Atg8 homologues. Dashed line indicates orientation of 











Figure 2.11. Human LC3 does not bind PfAtg3. Binding to the MBP–PfAtg3 CM3 chip was determined 
by SPR with triplicate injections of PfAtg8CM (in blue) and hLC3 (in green) at seven concentrations. Left: 




Figure 2.12. Multiple sequence alignment of Atg3 homologues. The newly identified AIM is marked 
with a purple bar and is conserved across Plasmodium species. Green bar denotes the handle region of 
yeast Atg3 shown to bind ScAtg8. Sequences were aligned with ClustalW2 (134) 




















Figure 2.13. Conservation of PfAtg8 surface residues. Pf, Pv, and PbAtg8 and human homologues, LC3, 
GATE-16, and GABARAP, were aligned with ClustalW2 (134) 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and visualized on the PfAtg8 structure using the ConSurf 
server (http://consurf.tau.ac.il/) (135, 136). PfAtg3103-110 is shown as stick model in green. Abbreviations: 
























Sections currently submitted as: 
Hain et al. Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the 
MMV Malaria Box active in blood and liver stage P. falciparum parasites.  





 Atg8 is an ubiquitin-like autophagy protein in eukaryotes that is covalently 
attached (lipidated) to the autophagosome membrane. Autophagy is increasingly 
appreciated as a target in diverse diseases from cancer to eukaryotic parasitic infections. 
Much of the autophagic machinery is conserved in the malaria parasite, Plasmodium 
falciparum, including the conjugation pathway for Atg8 lipidation. Although Atg8’s 
function in the parasite is not well understood, it is essential for Plasmodium growth and 
survival and localizes to the apicoplast, an indispensable organelle in Apicomplexans. 
We pursued independent strategies to identify unique inhibitors, such as fragment and 
library screening with SPR and in silico docking.  Here we describe identification of 
inhibitors for the protein-protein interaction PfAtg8 and its E2-conjugating enzyme, 






 With vital and diverse roles in cell stress and survival, autophagy is seen as a 
potential target in many diseases, including cancer, neurodegeneration, and protozoan 
infections (68, 137, 138). The Atg8-Atg3 interaction has emerged as an important 
modulator of Atg8 lipidation and overall levels of autophagy. In mammals, the viral 
FLICE-like inhibitor protein (FLIP) binds Atg3 and competes for LC3 interaction to 
prevent LC3 lipidation and autophagy-mediated host cell death (139). We envision a 
similar strategy in developing a small molecule compound that will disrupt the Atg8-
Atg3 interaction in the malaria parasite. 
 Although drug design has long focused on targeting enzyme active sites, PPIs are 
considered by many to be the next generation of drug targets (140). Targeting PPIs both 
increases the number of potential targets, as there are estimated to be approximately 
400,000 PPIs in humans (141), and allows for selectivity. Recent successes such as 
completion of Phase II clinical trials by navitoclax against Bcl-2 family proteins 
demonstrate the specificity in targeting non-active sites (142). Navitoclax exhibits high 
affinity for Bcl-2, Bcl-XL, and Bcl-w, but not the other Bcl-2 family prosurvival 
members, Mcl-1 and A1 (143). Other successes include inhibition of the BRD4/histone 
interaction in squamous carcinomas (144) and the MDM2-p53 interaction to slow tumor 
growth (145). Though the cancer field has led the way in PPI drug development, the 
strategy is being sought in other diseases, including HIV and parasitic infections (140, 
146, 147).  
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 There are several approaches to targeting a protein-protein interaction. In vitro 
high-throughput screening (HTS) against a molecular drug target is a popular choice as 
once the setup is established it is widely applicable to a range of drug targets and will 
likely lead to initial hits. However it does not provide molecular information of where 
and how the drug is binding the protein, making further optimization difficult. A 
powerful alternative is structure-based drug design (SBDD) because the binding mode is 
revealed. X-ray crystallography, nuclear magnetic resonance (NMR), or even in silico 
docking against the known structure are SBDD methods that can be used both for initial 
screening and optimization further down the drug design line. Figure A.1 diagrams an 
overview of to the drug design approach from target identification to clinical trials.  
 
Virtual library screening  
 Virtual library screening, an in silico method where compounds are docked to the 
known protein structure, has several advantages over empirical screening.  Inherently 
virtual libraries can be much larger and more comprehensive than physical compound 
libraries. Although computation-intensive, compounds can be sampled more quickly. 
Additionally VLS is not dependent on the ability to obtain robust crystals for crystal 
soaking experiments or the stability of the protein in NMR experiments.  
 Unfortunately, there are also impediments to the success of VLS. The enormous 
flexibility inherent in receptor-ligand complexes makes screening all possible 
conformations difficult. However programs are increasingly able to handle these 
difficulties, rapidly sampling an exhaustive set of ligand conformations and using a range 
of rigid to semi-rigid to fully flexible protein receptors (148, 149). Although there are still 
 62
setbacks, VLS can predict known ligands for a given receptor correctly, docking them in 
the correct pose 40-60% of the time (150).  
 
Fragment screening  
 Compared to typical drug-like compounds, screening molecular fragments, 
molecules between 100 to 300 daltons, samples chemical space more efficiently (151). 
Generally fragments follow the rule of three for hydrogen bond donors and acceptors, 
number of rotable bonds, and ClogP, and have an upper limit on polar surface area of 60 
Å2 (152). Because of their smaller size, molecular fragments bind weakly, with KDs in the 
0.1 to 1 mM range but the ligand efficiency is expected to be high, allowing for 
optimization without surpassing a drug-like size (153, 154). Additionally, the likelihood 
of a hit is higher compared to HTS and allows for the development of compounds that 
would not have been identified otherwise (155). Of the fragment-based drug design 
(FBDD) successes in clinical trials, most target kinases (156, 157). PLX-4032, targeting 
the kinase B-Raf in metastatic melanoma is on course to become the first clinically 
approved drug arising from a FBDD program (158, 159). Examples of FBDD-derived 
compounds in phase 2 clinical trials include an Aurora kinase inhibitor for cancer, an 
agonist of proliferator-activated receptor in type 2 diabetes, and the PPI inhibitor, 
navitoclax against Bcl-2/Bcl-xL in cancer (142, 160, 161).  
 Fragment-based approaches center on the ability to “grow” the molecule in steps 
using structure-activity relationships (SAR) and SBDD to eventually create a potent 
drug-like molecule. The anticipation is the creation of a more efficient ligand than would 
have been identified through traditional drug screening approaches. Alternatively, one 
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can identify fragments that bind in two nearby pockets and link them together. While this 
method has been successful, it is important to ensure the linker does not strain the 
attached molecules or change their orientation (162-165). If the pockets are too far apart 
the tethered molecule may be too large to be bioavailable and cell permeable. 
 The most well known methods to identify fragments are NMR, SPR, and X-ray 
crystallography. In fragment cocktail crystallography (FCC), protein crystals are soaked 
with a milieu of small molecular weight compounds. Changes in electron density indicate 
binding to the crystallized protein. While extremely powerful in terms of providing 
detailed knowledge on binding mechanism, FCC is dependent on the ability to obtain 
reliable, well-diffracting crystals of the protein. Additionally, this method may miss 
molecules that destabilize the crystal lattice and prevent diffraction. 
 SPR experiments have become a standard technique for fragment and drug 
screening, especially in industry. Detection of binding by SPR typically involves 
immobilization of one ligand onto an SPR chip. The analyte is passed over the 
immobilized protein ligand and changes in refractive index near the surface, due to ligand 
binding, is read out as SPR response. A great strength is that the Biacore sensor is 
sensitive enough to measure binding of molecular fragments around 100 daltons to a 
protein many times its size as long as a high density of immobilization is reached, 
described by the following formula. Maximal SPR response (RUs) = 
(MWAnalyte/MWLigand) x stoichiometry of binding x RL, where RL is the amount of 
immobilized ligand in RUs.  
 Previous studies using simultaneous approaches of empirical and virtual screening 
have identified distinct classes of ligands that would have been overlooked by either 
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approach alone (166). Pursuing a multi-pronged approach of in silico and in vitro 
screening combined with SBDD will increase the probability of identifying novel 
inhibitors of the Plasmodium autophagy system. Our structural and biochemical studies 
presented in Chapter 2 suggested the PfAtg8-PfAtg3 interaction was exploitable to 






 We attempted to obtain crystals suitable for soaking experiments. The PfAtg8 
crystals obtained in Chapter 2, with the PfAtg3103-110 peptide did not diffract reliably, 
requiring time-consuming screening of identical crystals at the synchrotron source. 
Additionally, the presence of the PfAtg3-peptide in the crystals prevents soaking with 
compounds competing for the W- or L-site. We attempted to optimize these crystals and 
obtain crystals of PfAtg8 alone for crystallography soaking experiments. Numerous 
constructs (Table A.3), purification schemes, matrix screens, and additives failed to yield 
diffracting crystals. While continuing to pursue this extremely powerful structural 
technique, we undertook alternative methods to identify inhibitors.  
 
Identification of PfAtg8-binding fragments   
 We chose to screen a library of 352 small molecular fragments from Zenobia 
Therapeutics, Inc. with an average molecular weight of 150 Da because of the high 
solubility, non-toxic nature, and functional diversity of the compounds as well as the 
compatibility of the library with fragment-based co-crystallization experiments. We 
utilized SPR-based differential fragment screening in order to identify fragments that 
bind the W-site of PfAtg8, important for the Atg8-Atg3 interaction. Binding of injected 
molecules to immobilized His6-PfAtg8WT and the W-site mutant His6-PfAtg8K19E/K47E 
was compared (Figure 3.1A,B). Hits eliciting 1.5 x’s the response (RU) over noise and 
1.5 x’s greater normalized binding for wild type than mutant were further validated for 
PfAtg8 binding with TSAs (Figure 3.1C). Likely due to the high internal fluorescence of 
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F410 and F470, we were not able to measure the effect of these compounds on the Tm of 
PfAtg8. Three fragments, F268, F408, and F537, showed significant binding in the TSA 
and were tested, along with F410, for their ability to inhibit the PfAtg8-PfAtg3 
interaction in SPR competition studies. PfAtg8CM was injected at a constant concentration 
over the MBP-PfAtg3 chip with an increasing concentration of fragments F268, F408, 
F410, and F537. While F268 and F537 showed no inhibition, two benzenetriols led to 
dose-dependent inhibition (Figure 3.1D). F410, benzene-1,2,3-triol and F408, benzene-
1,2,4-triol, inhibited the PfAtg8-PfAtg3 interaction with an IC50 of 150 µM and 1 mM, 
respectively. With higher concentrations of F410, the response levels off and slightly 
increases with the highest concentration. This was due to F410 binding to the MBP-
PfAtg3 chip as injection of F410 alone led to a concentration-dependent response (Figure 
A.2). Therefore the actual IC50 may be lower.  
 
Optimization of hydroxybenzene fragments with an oxime library  
 In lieu of structural information of benzenetriol’s binding mechanism, we sought 
to screen for more potent hydroxybenze derivatives. We utilized an oxime library 
approach, where two aldehyde building blocks are linked together through dialkoxyamine 
linkers to create a bivalent library (167). Our lab had previously synthesized an oxime 
screen together with Dr. J. Stivers (Johns Hopkins School of Medicine) for another 
molecular target. The R1 group, 3,4-dihydroxybenzaldehyde, was similar to the 
benzentriols we identifited in our Zenobia fragment screen leading us to screen this 
library against PfAtg8-PfAtg3 (Figure 3.2A). 3,4-dihydroxybenzaldehyde was tethered to 
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240 different R2 aldehydes with linker lengths ranging from two to four carbons (Figure 
3.2B).  
 We screened the library using a surface plasmon resonance (SPR)-based 
competition assay where PfAtg3 is immobilized onto an SPR chip and PfAtg8CM is 
injected in the presence of DMSO or a compound and binding is measured by the SPR 
response. Three compounds led to at least 50% inhibition in binding, two of which were 
derivatives of benzenetriols, similar to our Zenobia fragment hits (Figure 3.2C). Follow-
up experiments failed to validate dimethylbenzaldehyde as a hit but confirmed inhibition 
by 3,4,5-trihydroxybenzaldehyde.   
 In the original screen, each well contained a mixture of 12 reactants because of 
the varying linker lengths and the formation of heteromeric and homodimeric 
compounds. We sought to deconvolute which of the linker length species led to the 
observed inhibition. Reactions were set up with only one linker length and tested with 
SPR. Binding was decreased the most with a three-carbon linker but the difference was 
not significant (Figure A.3A). In thermal shift assays, all of linker length species 
increased the melting temperature of PfAtg8 (Figure A.3B). Therefore, it is unclear 
which of the linkers are responsible for inhibition in the original screen. We set up co-
crystallization matrix screens of PfAtg8CM with the two and three-carbon species 
individually. Several conditions led to crystals in one or both of the compounds, absent in 
the protein only control, but these crystals did not diffract at the SSRL synchrotron 
source.  
 
Virtual library screening to identify Plasmodial Atg8 inhibitors 
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 Because the A-loop region of PfAtg8 is divergent from human Atg8 homologues, 
we sought to identify A-loop-binding compounds. Using our crystal structure (PDB code 
4EOY), a PfAtg8 receptor was prepared in fred_receptor (www.eyesopen.com) for in 
silico docking studies (168). A suite of libraries consisting of FDA-approved drugs, the 
Medicines for Malaria Venture (MMV) malaria box, and Chembridge CORE, totaling 
nearly 400,000 compounds, was docked against the receptor with FRED 
(www.eyesopen.com) (168) (Figure 3.3A).VLS hits were ranked according to 
chemgauss3 score, known toxicity data, diversification, predicted solubility, and balance 
between polar and apolar interactions. Fifteen compounds were purchased from Hit2Lead 
and tested in vitro for inhibition of the PfAtg8-PfAtg3 interaction using SPR (Figure 
3.3B). Many of the compounds predicted to bind PfAtg8 led to inhibition. C25 and C24, 
the best hits, were chosen for verification of dose-dependent inhibition of the interaction. 
Only C25 led to dose-dependent inhibition with an IC50 of 18.5 ± 2.1 µM (Figure 3.4A). 
C25 led to dose-dependent decrease in the Tm of PfAtg8CM, measured in thermal shift 
assays, indicating binding to PfAtg8, but also that the compound may not be well suited 
for co-crystal matrix screening due to its destabilizing effect on PfAtg8 (Figure 3.4B). Of 
note, C25 had the second highest ranking in the original docking screen, docking pose is 
shown in Figure 3.4C,D.   
 
Identification of inhibitors from the MMV Malaria Box library 
 The MMV Malaria Box of 200 drug-like and 200 probe-like molecules was 
screened with our established SPR-based competition assay against the PfAtg8-PfAtg3 
interaction (Figure 3.5A) (169). Compounds leading to at least twenty-five percent 
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inhibition of binding were further tested for dose-dependent inhibition using SPR (Figure 
3.5B). Three of the six primary hits demonstrated a constant level of inhibition 
independent of concentration of the small molecule and were not further investigated. 
The other three compounds led to dose-dependent inhibition with an SPR inhibitory 
concentration ranging from six to 18 µM (Figure 3.5C). Interestingly, these compounds 
shared a common scaffold: 4-pyridin-2-yl-1,3-thiazol-2-amine (abbreviated here as PTA), 
incorporated as the N-substituent in various anilines or benzamides. For simplification we 
will refer to these compounds based on their plate ID and well position in the MMV May 
2012 plate setup: PAH9 (N-(4-methylphenyl)-4-pyridin-2-yl-1,3-thiazol-2-amine), PAC5 
(2-methylsulfanyl-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide), and PBB8 (2-bromo-
N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide) (Table 3.2). Hits were tested for their 
effect on the stability of PfAtg8CM using fluorescence-based thermal shift assays (TSAs). 
None of the compounds significantly affected the melting temperature (Tm) indicating the 
compounds did not impact the tertiary structure of PfAtg8 (Figure 3.5D).    
 
Determination of the PTA binding site on PfAtg8  
 We tested whether these compounds bound directly to PfAtg8 using SPR. 
PfAtg8CM was immobilized onto an SPR Ni-NTA chip via a twelve histidine N-terminal 
tag. PAH9, chosen for its better solubility, was injected over the chip and binding was 
measured. PAH9 led to a dose-dependent increase in SPR response, indicating binding to 
PfAtg8CM (Figure 3.6A). We next sought to determine the binding site for the PTA 
compounds with in silico docking. 
 70
 The OpenEye software package (www.eyesopen.com) (168) was used to dock 
conformers of the compounds against the X-ray structure of PfAtg8 (PDB code 4EOY) 
(45). All three compounds docked to the W-site of PfAtg8 (Figure 3B). PBB8 and PAC5 
bound with the pyridine ring in the W-site, whereas PAH9 was predicted to bind with the 
pyridine ring in the L-site, the thiazole ring positioned between the pockets and the 
methylbenzene group in the W-site. An alternate pose was enriched within the top ten 
poses output by the docking study, where PAH9 is contained solely within the W-site in a 
more compact conformation. It is worth mentioning that PAH9 is missing a donor oxygen 
compared to PBB8 and PAC5 and therefore may adopt a different mode of binding to the 
W- and L-sites of PfAtg8. PAC5 docked with the pyridine ring in the W-site and the 
methylsulfanylbenzene group bound to the L-site of PfAtg8. Docking was repeated using 
a version of the receptor for which the carbonyl of Lys47 was defined as a hydrogen bond 
acceptor constraint (Figure BA inset). PBB8 had the same docking pose in both studies. 
PAH9 had similar binding pose to the highest ranked pose from the unconstrained 
docking, while PAC5 was slightly different, with the pyridine ring rotated 90ºC in the W-
site and the benzene ring positioned just below and to the left of the L-site pocket, with 
the methylsulfanyl group reaching into the mostly hydrophobic L-site.  
 
Synthesis of a novel PTA derivative with a functional handle  
 Our studies indicated that the PTA scaffold is a good platform for hit-
optimization.  David Bartee in Dr. C. Myers laboratory (Johns Hopkins University) 
synthesized a PTA-benzaldehyde derivative, 4-formyl-N-(4-pyridin-2-yl-1,3-thiazol-2-
yl)benzamide with a functional handle extending off the common hydrophobic ring 
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system, termed PTA-AL (Table 3.2, Figure 3.7A). PTA-AL was prepared from 
commercially available PTA and 4-formyl benzoic acid through a DCC-promoted amide 
coupling. The benzaldehyde derivative, PTA-AL, can be tethered through a 
dialkoxyamine linker to a library of aldehydes and screened using our primary SPR 
competition assay against the PfAtg8-PfAtg3 interaction (167). Docking against PfAtg8 
suggests it is possible for an extension of the aldehyde to occupy the A-loop pocket 
(Figure 3.7B). A gain in parasite selectivity for such bifunctional analogs is expected as 
the A-loop is missing in the human Atg8 homologues (45). To confirm binding to 
PfAtg8, we tethered PTA-AL to (+)-biotinamidohexanoic acid hydrazide (BACH), 
through its reactive aldehyde group and tested binding with SPR. The biotinylated PTA 
compound, PTA-Biotin, was immobilized onto a neutravidin coupled SPR chip. His12-
PfAtg8CM injected at various concentrations PfAtg8CM led to a dose-dependent increase 
in SPR response, indicating PfAtg8 directly binds PTA-Biotin (Figure 3.7C).  
 Dr. C. Myers lab then converted PTA-AL to the hydrochloride salt and subjected 
it to acid-catalyzed acetal formation with methanol and trimethyl orthoformate under 
microwave irradiation to provide the dimethyl acetal PTA-D0, an unreactive derivative, 
to confirm activity of the starting platform (Table 3.2, Figure 3.7A). PTA-D0, 4-
(dimethoxymethyl)-N-(4-pyridin-2-yl-1,3-thiazol-2-yl)benzamide, has similar shape and 
distribution of acceptor and donor pairs as the original PTA compounds. Docking of the 
unreactive PTA-D0 compound suggested similar binding to the W- and L-site of PfAtg8 
as PAC5 with the functional group for extension pointing in direction of the A-loop 
pocket (Figure 3.7B). SPR studies confirmed PTA-D0 inhibited the PfAtg8-PfAtg3 
interaction with an IC50 of 2.86 µM in SPR (Figure 3.7D).  
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Inhibition of Plasmodium blood stages  
 The IC50s for the MMV compounds in P. falciparum 3D7 blood stages are 
previously reported and located on the NCBI PubChem database 
(http://pubchem.ncbi.nlm.nih.gov). The reported IC50 for PBB8 ranged from 1.36 to 4.52 
µM, while PAC5 ranged from 0.20 to 6.8 µM (PubChem bioassay ID (AID): 660866 and 
449707) (170). PAH9 has a reported IC50 of 350 to 400 nM (PubChem AID: 660866 and 
449703) (171). We focused on PAH9 for further studies because the reported cytoxicity 
in human cell lines is much lower compared to PAC5 and PBB8 (PubChem AID: 
660872, 685525, and 449705). 
 We measured growth inhibition of P. falciparum 3D7 blood stage cultures by 
C25, PAH9, PTA-D0, and the well-characterized antimalarial chloroquine (CQ) using the 
SYBR green I assay (172) in collaboration with Dr. D. Sullivan (Johns Hopkins 
University, USA). This assay exploits the absence of nuclei in erythrocytes with a 
fluorescent dye that is unquenched upon binding to nucleic acids, preferentially double-
stranded DNA. In two of three independent experiments, the IC50 of PAH9 was 768 nM, 
similar to previously published results, while in a third experiment, the IC50 was 3.3 µM, 
resulting in an average IC50 of 1.61 µM ± 1.47 (171). PTA-D0 had a similar potency as 
PAH9 against the blood stage of P. falciparum, with an average IC50 of 1.48 ± 0.6 µM. 
C25 was less potent with an IC50 of 19 ± 6 µM. In our assay CQ had an IC50 of 3 ± 2 nM 
(Figure 3.8).    
 
Inhibition of Plasmodium liver stages C25 and PAH9  
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 PfAtg8 is expressed and lipidated during the liver stage where it partially localizes 
to the apicoplast (38). Treatment of early liver stage parasites with the autophagy 
inhibitor 3-methyladenine is reported to delay conversion of the parasite into its 
trophozoite form (36). We therefore hypothesized that our PPI inhibitors PAH9 and C25 
would have activity against the liver stage. PAH9 was previously tested in P. yoelii liver 
stage cultures and did not display >50% inhibition at the screening concentration of 10 
µM; an IC50 was not reported (pubchem AID: 602118 and 602156) (173, 174). P. yoelii 
and P. berghei are often used to test drugs for liver stage inhibition as they are easier to 
culture. However, these are rodent malaria models and may not be indicative of activity 
in P. falciparum. Analysis of the W/L-site revealed differences in the amino acid 
composition that could affect drugs predicted to bind in that region (Figure A.4). We 
utilized a recently established P. falciparum liver stage in vitro model whereby 
sporozoites isolated from infected mosquitos’ salivary glands invade HC-04 hepatocytes 
(175). HC-04 is a unique immortalized cell line, with expression of biochemical markers 
characteristic for normal hepatocytes, allowing the full development of the human 
malaria parasite, P. falciparum (175-177).  
 With the help of Dr. J. Levitskaya (Johns Hopkins University, USA) we used this 
system to assess the effect of PAH9 and C25 on the development of P. falciparum 3D7-
GFP parasites (178) in human hepatocytes cultures. No change in the viability of HC-04 
cells was detected in response to treatment with 3 µM or 30 µM of PAH9 or C25 during 
the 96 hr treatment (Figure 3.9). We observed a 45% reduction in the proportion of 
hepatocytes infected with P. falciparum 3D7-GFP sporozoites (GFP+/PI- cells) in 
response to treatment with 30 µM, but not 3 µM of PAH9 (Figure 3.10A). Additionally, 
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there was a dose-dependent reduction in the intensity of GFP fluorescence at both 
concentrations of PAH9, indicating inhibition of parasite development within 
hepatocytes, at least in vitro (Figure 3.10B). C25 had little effect on GFP fluorescence 
intensity, but did decrease the number of infected cells by 30% at 30 µM (Figure 
3.10A,B). Because C25 and PAH9 did not affect cell survival or cell growth of HC-04 
cells, the compound’s effect on the parasite is unlikely to be a result of host cell toxicity. 
  
Validation of drug effect on PfAtg8 in parasite cultures 
 We next sought to determine whether PAH9 or C25 had a direct effect on PfAtg8 
in P. falciparum blood stage cultures. In immunoblot assays, we observed a very faint 
band corresponding to PfAtg8 in DMSO-treated control cells (Figure 3.11). Incubation of 
cells in minimal media lacking human serum for six hours led to a very slight increase in 
PfAtg8. In contrast, treatment with 50 µM PAH9 for five hours led to a drastic increase 
in PfAtg8 protein levels as well as a shift in mobility, likely corresponding to the 
unlipidated form of PfAtg8. PfAtg8 protein levels were also increased, though not to the 
same extent with 100 µM C25 and led to a similar shift in mobility. We also looked at 
heat shock protein 70 (PfHsp70) in treated cells. Interestingly, PfHsp70 was present at 
the expected molecular weight of 73 kDa in control and starved cells, while PAH9-
treated cells had a fainter band at this size and a prominent band at 35 kDa, possibly 
indicative of a cleavage product.  
 
Attempts to obtain structural information 
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 Although crystals of PfAtg8 with our compounds have not been obtained, nuclear 
magnetic resonance (NMR) could alternatively be used to provide molecular information 
on binding. Prior to solving the structure of PfAtg8-PfAtg3103-110 with X-ray 
crystallography, we pursued NMR experiments on PfAtg8CM with the help of Ananya 
Mayumdar at the JHU NMR facility. The initial 1H-15N Heteronuclear Single Quantum 
Coherence (HSQC) 2D spectrum showed a good dispersion of peaks, indicative of a well-
folded protein, but Atg8 was subsequently found to be too unstable to collect a complete 
data set and acquisition of NOESY spectrum was not possible (Figure A.5). This was due 
to irreversible precipitation of PfAtg8 above 25ºC after 24 hours, leading to a low signal 
to noise ratio. However, data collection at lower temperatures may allow for sufficient 
protein stability in the future. Potentially, the binding site for C25, benzene-1,2,3-triol, 









 Targeting protein-protein interactions has long been overlooked in the drug 
development field. PPIs usually involve shallower pockets and a more extensive network 
of residues than enzymatic active sites so that a small molecule must mask an area of 
800-1000 Å2 to competitively inhibit the interaction (156). However PPIs are less 
conserved than active sites (179), offering the opportunity for more selectivity, an 
important concept when targeting a eukaryotic parasite protein within a eukaryotic host. 
Using a combination of approaches, we have identified three starting platforms against 
the PfAtg8-PfAtg3 interaction. 
  Two benzenetriols were identified from the Zenobia fragment screen as inhibitors 
against the PfAtg8-PfAtg3 interaction. Benzene-1,2,3-triol showed the greatest inhibition 
with an IC50 of 150 µM. Our SPR experiments suggest the fragments compete for binding 
of Trp105 of Atg3 in Atg8’s W-site. The observed inhibition of our fragments falls 
within the expected range for small molecule fragments (153, 180). Benzenetriol was 
independently identified as a hit in our oxime library screen. Although the screen was 
chosen because of the similarity of R1 group to the benzenetriol, it appears the 
benzenetriol and benzenediol, at least when combined in a divalent molecule, bind in 
different pockets.  
 We also used an in silico approach to target the A-loop pocket of PfAtg8. This 
approach led to the discovery of a compound that inhibits the Atg8-Atg3 interaction and 
shows activity in blood and liver stages. Though the potency is sub-optimal, C25 was 
well tolerated in human liver cells at high micromolar concentrations. It may be 
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worthwhile to pursue optimization of C25 through SAR studies and would be of great 
interest to determine if C25 binds the A-loop pocket, as predicted in our docking studies. 
C25 may be better suited as a molecular probe to elucidate the function of PfAtg8 during 
different stages of the malaria life cycle as its function is currently unclear (181). 
 Using in vitro screening, we identified PTA, N-(4-methylphenyl)-4-pyridin-2-yl-
1,3-thiazol-2-amine,  as a scaffold inhibiting the PfAtg8-PfAtg3 interaction. We 
demonstrated activity in blood- and liver-stage Plasmodium parasites by one PTA 
compound, PAH9. All PTA-containing MMV compounds had a Ligand Efficiency by 
Atom Number (LEAN) score greater than 0.3 in the blood stage, indicative of high ligand 
efficiency and a promising starting point for expansion (182). PAH9 was previously 
reported to have low cytotoxicity with a LD50 (lethal dose) of 18.2 µM in HepG2 cells 
and half maximal cytotoxic concentration (CC50) and IC50 of 32 µM in Huh7 cells 
(PubChem AID: 685525, 660872, 449705). PAH9 only inhibited liver stage parasites 
significantly within the reported cytotoxic range in human cells, although no cell death 
was observed in HC-04 cells at these concentrations in our study.  
 Treatment of P. falciparum with high levels of PAH9 led to a drastic increase in, 
presumably unlipidated PfAtg8 protein levels. This increase could be due to an up-
regulation of PfAtg8 synthesis to compensate for inhibition or a buildup of existing 
protein levels due to a blockade in autophagic degradation. In yeast, nitrogen starvation 
leads to induction of Atg8 expression while inhibition of later stages of autophagy leads 
to accumulation and even greater protein levels of Atg8 (183, 184). Further studies are 
necessary to determine if PfAtg8 is upregulated at the transcriptional, translational, or 
degradation level in response to PAH9 treatment. The intriguing effect of PAH9 on 
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PfHsp70 was unexpected and may indicate a cellular response to stress induced by 
inhibiting Atg8 lipidation. The putative Hsp70 cleavage fragment of ~30-35 kDa is 
reminiscent of Hsp70.1 cleavage observed in hippocampal cornu Ammonis neurons in 
response to ischemic stress. Hsp70.1 in these cells is carbonylated and cleaved by µ-
calpain, leading to lysosomal rupture, release of cathepsin, and subsequent neuronal death 
(185). It is premature, yet tempting, to envision a similar stress pathway in Plasmodium 
activated under prolonged exposure to high concentrations of PAH9. It has been 
previously shown that cytocidal levels of CQ leads to food vacuole permeabilization and 
features of programmed cell death in P. falciparum (186). In the future, we could 
examine Hsp70 fragmentation under CQ treatment.  
 Of note, the IC50 of PAH9 in parasite cultures was lower than the IC50 measured 
with SPR. This could be due to an accumulation of the drug inside the parasite or because 
even slight inhibition of PfAtg8 lipidation has drastic effects on parasite growth, similar 
to reaching the tipping point on a balance or could be due to off-target effects. The IC50 
of C25 and PTA-D0 was in good agreement in the SPR and parasite growth assays.  
 Autophagy is increasingly being targeted in certain types of cancer (187). Our 
identified inhibitors, and their derivative compounds will be tested for inhibition of the 
human Atg8-Atg3 interaction in vitro to determine toxicity and alternative utilization as 
leads in cancer drug development.  
 
Future directions:  
 We are currently in the process of creating an oxime library with our PTA-AL 
derivative in collaboration with Dr. C. Myers (Johns Hopkins University). Because of the 
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difficulties deconvoluting the dihydroxy screen, we will synthesize the PTA-AL screen to 
contain one species per well. In the near future, this library will be screened using the 
Atg8-Atg3 SPR-competition assay with the hopes of identifying a compound with better 
inhibition in the asymptomatic liver stage. It is of great interest to test these inhibitors 
against P. vivax dormant hypnozoite forms, though these studies would be more cost 
intensive, requiring a mouse model.  
 Now that we have identified promising candidates, it is crucial to obtain structural 
information to guide further changes. The ability to synthesize the PTA derivatives in 
collaboration with Dr. C. Myers, allows us to pursue co-crystallization matrix screens. 
Table A.3 illustrates the numerous constructs of PfAtg8 that we have attempted to 
crystallize. Some of these constructs could be re-screened with our inhibitor molecules.  
In addition to its potential for development into a therapeutic drug, PAH9 could serve as 
a tool to elucidate the biological function of PfAtg8. Chapter 4 present preliminary results 






Methods & Materials 
 
SPR: SPR runs were conducted on a Biacore 3000 instrument (GE Healthcare). Unless 
otherwise stated, runs were performed in running buffer 2 (RB2) containing 354 µM 
KH2PO4, 1.87 mM Na2HPO4, 51.5 mM NaCl, pH 7.4, 0.01% v/v P20, 0.2 mg/ml BSA at 
25C (Quality Biologicals). See Chapter 2 Methods & Materials for RB1. Bound analyte 
was dissociated from the chip using 1 injection of 1 M MgCl2 followed by 2 blank 
injections of RB between each concentration. Binding and equilibrium constants were 
determined with Scrubber (BioLogic™). A double referencing method was applied to 
correct for nonspecific binding to the chip with interspersed blank injections correcting 
for baseline drifts. Changes in refractive index from DMSO were adjusted with a DMSO 
calibration curve. 
 Identification of fragments that bind Atg8 near the cargo receptor site: His6-
PfAtg8 WT and K19E/K47E were immobilized with maximal levels onto different 
flowcells of an NTA-Chip (GE Healthcare) preconditioned with nickel. A library of 352 
fragments (library 1 from Zenobia Therapeutics, Inc.) was screened for binding at a 
concentration of 0.1 mM diluted in running buffer containing 50 mM HEPES pH 8, 50 
mM NaCl, 3% DMSO, 0.005% v/v P20. 50 µL of each compound was injected at 20 
µL/min and dissociation time of 150 sec.  
 PfAtg3 immobilization: A CM3 or CM5 surface chip (GE Healthcare) was pre-
conditioned with multiple injections of 20 mM glycine pH 2.2 prior to pH scouting for 
identification of optimal binding conditions of Atg3 to the sensor chip. MBP-PfAtg3 or 
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His6-PfAtg3, dissolved in 10 mM Na Acetate pH 4.0, was immobilized by amine 
coupling. 
 Dose-dependent inhibition by fragment: His6-PfAtg8CM at a constant final 
concentration of 250 nM was injected in the presence of a 2-fold dilution series of 
fragments starting at 1 mM, with eight concentrations over His6-PfAtg3 CM3 chip. RB1 
contained 3% DMSO and no BSA. Injections of His6-PfAtg8CM without fragment were 
interspersed to control for loss of protein activity over time. Each concentration was run 
in triplicate at 50 µL/min with 30 µL injections and a 40 sec dissociation time starting 
with the lowest fragment concentration. 
 Competition screen with VLS compounds: 25 µL of 150 nM His6-PfAtg8CM, 
with either 500 µM compound or equivalent DMSO (0.5% v/v) in RB2 was injected over 
His6-PfAtg3 CM3 chip at 40 µL/min. IC50 determination for C25: 40 µL of 200 nM 
His6-PfAtg8CM, diluted in RB2 (0.2% DMSO), was injected over a MBP-tev-PfAtg3-
immobilized CM5 chip in the presence of increasing amount of C25 (7 2-fold dilutions, 
done in triplicate, highest compound concentration is 200 µM). His6-PfAtg8CM was 
dissociated from chip between injections using a 15-µL injection of 1 M MgCl2. 
 MMV SPR competition assay: MBP-PfAtg3 was immobilized onto a CM5 chip 
(GE Healthcare) as described previously with MBP immobilized on reference 
flowcell(45). Compounds were added to 300 nM His6-PfAtg8CM in RB2 (containing 3% 
DMSO) at a final concentration of 5 µM. 40 µL were injected, followed by a 12.5 µL of 2 
M MgCl2 for dissociation. Dose-dependent inhibition: 30 µL of PfAtg8CM at 200 nM 
was injected in the presence of a 2-fold dilution series of compound (highest 
concentration of 50 µM) or equivalent volume of DMSO (final DMSO concentration was 
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1%). Each injection was followed by a 10 µL injection of 2 M MgCl2. All measurements 
were conducted in triplicate. 
 Direct binding of PAH9 to PfAtg8CM: His12-PfAtg8CM was injected over an 
NTA-chip (GE Healthcare) preconditioned with nickel, leading to capture of 3,000 
response units (RUs).  Running buffer contained 3% DMSO. A 4 2-fold-dilution series of 
compounds, highest concentration of 75 µM, was injected over PfAtg8 variants at 40 
µL/min. 
 Direct binding of PTA-Biotin to PfAtg8CM: PTA-Biotin was injected over a 
neutravidin coated SPR chip (GE Healthcare) on one flowcell, with 130 RUs 
immobilized, while BACH was injected over a reference flowcell (150 RUs 
immobilized). His12-PfAtg8CM was injected in triplicate in running buffer containing 3% 
DMSO. Protein was dissociated from the chip after each cycle with 10 µL injection of 20 
mM HEPES pH 7.4, 1% w/v SDS regeneration solution.  
 
Thermal shift assay: Assays were conducted in 1x PBS with 1:1800 final dilution of 
SYPRO® orange dye (Invitrogen). Measurements made in triplicate for each condition. 
Concentration of His6-PfAtg8CM in assay was 65 µM. Fluorescence was measured from 
20 °C to 80 °C in a Biorad C1000™ thermal cycler. For MMV screen: 100 µM PTA 
compounds or equivalent volume of DMSO was added to His6-PfAtg8CM. C25 was added 
at increasing concentrations in triplicate up to 2 mM. Amount of DMSO in all conditions 
was kept constant.  
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Docking: Docking was conducted using the OpenEye software package using standard 
parameters if not specified otherwise (www.eyesopen.com) (168). VLS: The OpenEye 
software program fred_receptor was used to make an unconstrained receptor. A second 
receptor was created around the A-loop pocket with specific constraints to hydrogen bond 
with His67. Initial screening was conducted with the constrained receptor. Hits were 
screened with the unconstrained receptor to verify binding to the A-loop pocket. Omega2 
(188, 189) was used to generate 200 conformers for each compound in each library which 
were docked with FRED (168). Results were visualized using the OpenEye visualization 
software, VIDA.  MMV docking: An unconstrained receptor for PfAtg8 was made with 
make_receptor from OEDocking toolkit covering the whole molecule to detect potential 
binding pockets on the surface. Three main pockets (W-site, L-site, A-site) were 
identified with 377, 271, and 513 Å3 volumes, used in first docking studies. A second 
receptor was generated with specific constrains to the carbonyl of Lys47 as hydrogen 
bond donor. A maximum of 2000 conformers per compound was prepared with Omega2 
(188, 189) and docked onto constrained and unconstrained receptors with FRED (168). 
 
Synthesis of PTA derivatives: General. All reagents were obtained from commercial 
suppliers and used without further purication.  Acetonitrile was distilled after drying on 
CaH2 then stored over 3 Å molecular sieves. Yields of all reactions refer to the puried 
products. Dynamic Adsorbents 32 – 63 µm silica gel was used for flash column 
chromatography and 250 µm w/h F254 plates were used for thin layer chromatography 
(TLC). Microwave-assisted reactions were carried out using a Biotage Initiator 
Microwave Synthesizer (300 W). 1H and 13C NMR spectra were acquired on a Bruker 
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Avance III 500 spectrometer operating at 500 MHz for 1H and 125 MHz for 13C. 
Chemical shift values are reported as ! (ppm) relative to CHCl3 at ! 7.27 ppm and DMSO 
at ! 2.50 ppm for 1H NMR and CHCl3 at ! 77.0 ppm and DMSO at ! 39.51 ppm for 13C 
NMR. Mass spectrometry analysis was carried out at University of Illinois at Urbana-
Champagne, School of Chemical Sciences, Mass Spectrometry Laboratory. The purity of 
synthesized compounds was "95% as analyzed by HPLC (Beckman Gold Nouveau 
System Gold) on a C18 column (Grace Alltima 3 µm C18 analytical Rocket® column, 53 
mm × 7 mm) using 50 mM triethylammonium acetate buffer, pH 7, and acetonitrile 
(ACN) as eluent, ow rate of 3.0 mL/min, detection at 300 nm.  
 4-formyl-N-[4-(pyridin-2-yl)-1,3-thiazol-2-yl]benzamide (PTA-AL). Synthesis 
conducted by Dr. C. Myer’s lab. To a solution of 4-(pyridin-2-yl)-1,3-thiazol-2-amine 
(0.059 g, 0.33 mmol) in 2.0 mL ACN, the following was added sequentially: 76 mg 
dicyclohexylcarbodiimide (370 µmol), 50 µg 4-formylbenzoic acid (330 µmol), and 12 
mg N,N-dimethylamino pyridine (100 µmol). The mixture was heated at 50°C for 17 hrs, 
then allowed to cool to RT. Solids were removed by vacuum filtration, and the resulting 
filtrate was condensed under reduced pressure. The resulting yellow solid was re-
dissolved in 5.0 mL CHCl3 and 5.0 mL 1M HCl was added to give a yellow-tan emulsion 
at the liquid-liquid interface. This solid was collected by centrifugation at 4,000 rpm for 5 
min followed by manual collection of the resulting cake (this acid precipitation was 
necessary to remove closely eluting impurities). The solid was then purified by silica 
flash column chromatography (DCM:MeOH:Triethylamine 94:5:1) Rf =0.32 The product 
was obtained as a yellow powder (23 mg, 22% yield). 1H NMR (500 MHz, DMSO-d6) ! 
(ppm) = 12.95 (br. s., 1H), 10.13 (s, 1H), 8.63 (d, J = 3.93 Hz, 1H), 8.31 (d, J = 8.17 Hz, 
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2H), 8.07 (d, J = 8.33 Hz, 2H), 8.03 (d, J = 7.86 Hz, 1H), 7.92 (s, 1H) 7.91 (td, J = 2.00 
Hz, 8.75 Hz, 1H), 7.35 (ddd, J = 1.10, 4.79, 7.47 Hz, 1H) 13C NMR (500 MHz, DMSO-
d6) ! (ppm) = 192.90, 164.74, 158.91, 152.03, 149.54, 149.38, 138.50, 137.30, 137.15, 
129.41, 128.94, 122.88, 120.06, 112.30. HRMS (ESI) m/z: calc’d 310.0650 (M-H+); 
found 310.0651 (M-H+). 
 4-(dimethoxymethyl)-N-[4-(pyridin-2-yl)-1,3-thiazol-2-yl]benzamide (PTAD0). 
Synthesis conducted by Dr. C. Myer’s lab. PTA-AL dissolved in CHCl3 was treated with 
1M HCl as described above to form the hydrochloride salt. 40 µg of PTA-AL HCl (120 
µmol) was suspended in 500 µL MeOH and 10 µL trimethylorthoformate (910 µmol) was 
added followed by p-toulene sulfonic acid monohydrate (3 mg, 12 µmol). This solution 
was heated by microwave irradiation at 130°C in a sealed vial for 5 min and stirred at RT 
36 hrs, at which time a precipitate formed. The solvent was removed under reduced 
pressure and the residue was dissolved in 10 mL DCM and washed with saturated 10 mL 
NaHCO3 brine, and dried with Na2SO4. Condensation under reduced pressure yielded the 
product as a yellow powder (26 mg, 61% yield). 1H NMR (500 MHz, CDCl3) ! (ppm) = 
9.81 (br. s., 1H), 8.64 (d, J = 4.24 Hz, 1H), 7.96 (d, J = 8.17 Hz, 2H), 7.91 (d, J = 7.86 
Hz, 1H), 7.74 (s, 1H), 7.74 (td, J = 1.73, 7.70 Hz, 1H), 7.62 (d, J = 8.17 Hz, 2H), 7.22 
(dd, J = 4.95, 6.84 Hz, 1H), 5.47 (s, 1H), 3.35 (s, 6H) 13C NMR (500MHz, CDCl3) ! 
(ppm) = 164.24, 158.12, 152.24, 149.85, 149.62, 143.32, 136.84, 131.80, 127.51, 127.29, 





yl)benzamide (PTA-Biotin). Synthesis conducted by Dr. C. Myer’s lab. 25 µL 50 mM 
PTA-AL dissolved in DMSO was incubated with 20 µL 50 mM BACH (5-
[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-(6-
hydrazinyl-6-oxohexyl)pentanamide) (Sigma-Aldrich) dissolved in DMSO and 10 µL 
sodium acetate (pH 4.5) with 0.02% sodium azide at 37 °C O/N. Final concentration of 
PTA-Biotin was 18 mM.  
 
P. falciparum blood stage culturing: P. falciparum 3D7 and FCR3 cultures were 
maintained using modified, previously published methods at 37 °C, 2% hematocrit of 
human red blood cells (190). Complete culture media consisted of sterile RPMI 1640 
media (Life Technologies), supplemented with 10% human serum, 0.005% 
hypoxanthine, and buffered with final concentrations of 0.6% (w/v) HEPES and 
0.26% (v/v) NaHCO3. The FCR3 strain was maintained at 3% CO2 and 5% O2, 92% N2 
atmosphere, while the 3D7 strain was maintained at 5% CO2, 5% O2, 90% N2 
atmosphere. 
 
Immunoblot analysis of P. falciparum blood stage: P. falciparum FCR3 (generously 
provided by Dr, J. Smith, Seattle BioMed) asynchronous culture, 25% parasitemia, was 
washed in starvation media lacking human serum and resuspended in complete media 
with 50 µM PAH9, 100 µM C25 or equivalent DMSO, or starvation media with 
equivalent DMSO for five hours. RBCs were harvested with centrifugation and lysed 
with 0.2% saponin. Parasites were harvested by centrifugation and washed in 1x PBS 
with Complete EDTA-free protease inhibitors (Roche) and lysed by repeated vortexing 
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and boiling in SDS reducing sample buffer. Lysates were separated with SDS-PAGE on a 
15% polyacrylamide gel and subjected to western blotting with 1:400 !-TgAtg8 
(generously provided by Dr. P. Roepe, Georgetown University) and 1:1000 !-PfHsp70 
(generously provided by Dr. N. Kumar, Tulane University). HRP-conjugated secondary 
antibodies (Southern Biotech) were detected by SuperSignal West Femto (Thermo 
Scientific) or Amersham™ ECL™ Prime (GE Healthcare) chemiluminescent substrate. 
Total protein levels were visualized with ProAct™ Membrane Stain (Amresco) and 
quantified with ImageJ.(117)  
 
SYBR Green I growth inhibition assay. 10 µL of 10x compound diluted in RPMI 1640 
media (Gibco) with a constant concentration of 1% DMSO was added to a 96 well plate 
(Costar). 90 µL of 1.5% ring stage, synchronized with 5% w/v sorbitol P. falciparum 3D7 
parasites, 1% hematocrit, in culture media with 10% v/v human serum with 10 µg/mL 
gentamycin. Each compound concentration and 1% v/v DMSO controls were run in 
triplicate. Plates were incubated at 37C in 5% O2, 5% CO2 and 90% N2 for 72 hrs. Plates 
were frozen, thawed, and incubated with 100 µL 2xSYBR green in lysis buffer (20 mM 
Tris pH 7.5, 5 mM EDTA, 0.008% Saponin, 0.08% TritonX-100) in the dark for at least 
one hour. Fluorescence was measured with a plate reader (HTS 7000, Perkin Elmer) at 
excitation/emission wavelengths of 485/535 nm. 
 
In vitro infection of human hepatocytes with P. falciparum 3D7-GFP: HC-04 cells 
(ATCC, Manassas, VA, USA) were maintained in complete medium (IMDM) containing 
2.5% FCS, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine, 
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(GIBCO®, Life Technologies). P. falciparum 3D7-GFP parasite strain (178) was 
propagated in the Parasitology Core facility, Johns Hopkins Malaria Research Institute. 
In vitro infection of human hepatocytes was done as described previously (175). Briefly, 
salivary glands were dissected from infected Anopheles gambiae mosquitoes 17 days 
after exposure to infective blood meal. Sporozoites were isolated with an OptiPrepTM 
Density Gradient (Sigma-Aldrich) at 12,000 x g for 10 min, washed in complete medium 
and counted with a hemocytometer. Sporozoites were incubated with HC-04 cells at 3:1 
sporozoite to hepatocyte ratio for 2 hrs at 37ºC. Cells were incubated with DMSO, 3 µM 
or 30 µM of PAH9 or C25 in complete media, replenishing media and compound after 48 
hrs. Flow cytometry based detection of infected cells was done 72 hrs post infection 
using FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo 
software (Tree Star, Inc.).  
 HC-04 cell viability under 3 µM and 30 µM C25 and PAH9, or equivalent DMSO 
in complete media was assessed after 96 hrs. Annexin-V positive and PI-positive cells in 
hepatocyte cultures were detected by flow cytometry according to the manufacturer’s 
instruction (InvitrogenTM, Life Technologies).  
 
Nuclear Magnetic resonance: His6-PfAtg8CM BL21-RII cells were grown O/N as 
normal and expanded to 2 L in TB. At an OD600 of 2.2, cells were harvested at 3000 x g, 
4ºC, 20 min and the cell pellet was washed with chilled 1xM9 salt solution (3 g/L 
KH2PO4, 6.8 g/L Na2HPO4, 5g/L NaCl, pH 7.2) and centrifuge. The cell pellet was 
resuspended in isotopically-labelled minimal media (1xM9 salt solution, 1 g/L 15NH4Cl, 
6g/L Dextrose, 10 mg/L thiamine, 2 mM MgSO4, 0.1 mM CaCl2), grown for one hour, 
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induced with 0.5 mM IPTG, and grown O/N, 20ºC. Harvesting and purification with 
affinity tag, cation exchange, and size exclusion was performed the same as for unlabeled 
His6-PfAtg8CM with final buffer 25 mM MES, 5% glycerol, 0.5 mM MgCl2, pH 6.5. Data 
was acquired at 25ºC on an 800 MHz (1H) Varian Inova spectrometer at the JHU 














Table 3.2. Structures and inhibition data for PTA compoundsa  
 
aPTA-containing compounds used in studies listed with PubChem Compound Identification (CID), MMV 
ID, chemical structure, molecular weight (g/mol), IC50 in SPR and blood stage assays, and LEAN score, 















Figure 3.1. Identification of molecular fragments that inhibit PfAtg8-PfAtg3 interaction. A. Zenobia 
fragments were screened for binding to the W-site of PfAtg8 using SPR. PfAtg8 WT and K19E/K47E W-
site mutant were immobilized and fragments were injected. B. Chemical structure of fragments hits giving 
1.5xs response over noise for WT and at least 1.5x’s normalized response for WT over K19E/K47E (Mt). 
C. TSA of SPR hits with His6-PfAtg8CM. The melting temperature of His6-PfAtg8CM was measured with 
increasing concentration of fragments. D. SPR-based inhibition assay. His6-PfAtg8CM was injected over the 
MBP–PfAtg3-conjugated chip with increasing concentrations of fragment. Solid line indicates mean 















Figure 3.2. Screening of hydroxybenzene oxime library. A. Comparison of oxime library R1 group to 
fragment hits (in pink box) identified against PfAtg8. B. Reaction scheme for synthesis of hydroxybenzene 
oxime library. 240 different aldehydes were screened. Red dots denote injections of PfAtg8 with DMSO for 
baseline binding. C. Oxime library was screened using the PfAtg8-PfAtg3 competition assay with SPR at 




Figure 3.3. Virtual library screening for A-loop pocket binders. A. VLS compounds docked onto the 
structure of PfAtg8. B. In vitro screening of VLS compounds. PfAtg8 was injected over an SPR chip 
immobilized with PfAtg3 in the presence of DMSO or 15 VLS compounds. Bars represent mean and SD 






Figure 3.4. Dose-dependent inhibition with VLS compound, C25. A. Dose-dependent inhibition by C25. 
Curve is representative of two independent experiments with an average IC50 of 18.5 ± 2.1 µM. B. Docking 
of C25 to PfAtg8 (PDB code 4EOY). Hydrogen bond contacts between PfAtg8 residues and C25 are 
shown. Asterisk denotes contact to main chain nitrogen or oxygen. C. Human Atg8 homologue, GATE-16 








Figure 3.5. Identification of a common scaffold that inhibits Atg8-Atg3 from the MMV malaria box. 
A. Primary screen of MMV Malaria Box with SPR competition assay (169). Gray box denotes compounds 
meeting the threshold of greater than 25% inhibition. B.  Bar graph showing inhibition of hits in primary 
screen, denoted by plate position. C. Dose-dependent inhibition of PfAtg8-PfAtg3 interaction by MMV 
compounds. Inhibition was measured with increasing amount of compound in SPR competition screen. 
Mean and SD of 3 injections are shown. D. Thermal stability assay of PfAtg8CM with the three MMV hits. 














Figure 3.6. In vitro and silico studies on PfAtg8-PTA compound binding. A. Binding of PAH9 to 
PfAtg8. His12-PfAtg8CM was immobilized onto a nickel-charged NTA SPR chip. PAH9 was injected over 
variants in two separate runs at 4 concentrations. Graph shows mean ± SD of binding from PAH9. B. In 
silico docking of PTA compounds to PfAtg8CM (PDB code 4EOY). Overall structure of PfAtg8 with W- 
and L-site and A-loop demarcated. Below: best poses for each compound. The predicted pose for 
unconstrained docking is shown in cyan. Docking was also performed constraining to the carbonyl of 
Lys47, located between the W- and L-site. Predicted pose for constrained docking is shown in green. For 
PAH9, an alternate pose, highly ranked in the unconstrained docking and enriched in top ten poses is 









Figure 3.7. Synthesis of a PTA derivative with a functional handle. A. Reaction scheme for synthesis of 
PTA-AL and PTA-D0. B. In silico docking of PTA-derivatives onto PfAtg8. PTA-AL (yellow) and PTA-
D0 (green) were docked onto the constrained receptor of PfAtg8CM (PDB code 4EOY) with OpenEye 
docking suite (168).  C. Direct binding of PTA scaffold to PfAtg8. PTA was linked to biotin through a PEG 
linker and immobilized onto an SPR chip. PfAtg8 was injected, leading to dose-dependent binding 
(sensorgram shown in inset). D. Inhibition of PfAtg8-PfAtg3 interaction by PTA-D0. SPR response of 
PfAtg8 injected over immobilized PfAtg3 was measured in the presence of increasing concentration of 









      1             2             3 
Mean (µM) 
± SD 
CQ 0.005 0.007 0.002 0.003 ± 0.002  
PAH9 0.768 3.312 0.769 1.61 ± 1.47 
PTA-D0   - 1.050 1.900 1.47 ± 0.60 
C25 26.74 13.42 16.75 18.97 ± 6.92 
 
Figure 3.8. Inhibition of P. falciparum blood stages. SYBR green I assays were used to measure 
inhibition of parasite growth by CQ, PAH9, C25, and PTA-D0. Growth inhibition curves are shown for one 
experiment, with SD. IC50 values from two to three experiments are shown in table inset.  
  



































Figure 3.9. Effect of PAH9 and C25 treatment on viability of human HC-04 cells in vitro. Flow 
cytometry was used to detect Annexin-V and PI positive cells in HC04 hepatocyte cultures treated with 
C25 and PAH9. Dot plot graphs represent pattern of staining, bar graphs show mean and SD of viable cells 




Figure 3.10. Effect of PAH9 and C25 treatment on the development of P. falciparum 3D7 GFP 
parasite in HC-04 cells in vitro. A. Viable, P. falciparum-infected hepatocytes (GFP+/PI-) exposed to 
drug treatment were detected by flow cytometry 72 hrs post-infection. Dot plot is representative of pattern 
of staining. Numbers indicate percentage of GFP+ cells in PI- cell population. Bar graph shows mean and 
SD of three independent cultures. B. GFP fluorescence intensity of P. falciparum-infected hepatocytes 
exposed to drug treatment was assessed with flow cytometry. Histograms demonstrate one representative 
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staining pattern, numbers indicate mean fluorescence intensity (MFI) of GFP+/PI- populations. Bar graph 













Figure 3.11. PAH9 and C25 increase PfAtg8 protein levels. P. falciparum FCR3 was treated with 
DMSO (C), starved with incomplete media (IM), or C25 or PAH9 for five hours. Parasite lysate was 
separated with SDS-PAGE and PfAtg8 and PfHsp70 detected with Western Blot. Asterisk denotes 
expected molecular weight of Hsp70. Double asterisk denotes smaller band detected in PAH9 sample with 
mobility ~ 35 kDa. Double dot indicates mobility of control and starved sample, potentially the PE-
lipidated form of Atg8, which runs with faster mobility. Single dot indicates slower mobility of C25 and 
PAH9 treated samples, possibly representing the unlipidated form of Atg8. Below is membrane stained 









Chapter 4  







 Interest in autophagy has surged in the past five years and is now seen as a 
therapeutic target in many diseases including cancer, neurodegeneration, and infectious 
diseases. While much was known about the role of autophagy in the protozoans 
Leishmania, Trypanosoma, and Toxoplasma, the story is less conclusive for the malaria 
parasite Plasmodium. Atg8 is essential in Plasmodium but it is not known if a classical 
autophagy pathway exists. Suggested variations on traditional autophagy include roles in 
hemoglobin transportation, drug detoxification, and protein and organelle export to the 
parasitopherous vacuole and possibly beyond.  
 Atg8 homologues in other species are involved in diverse processes including 
trafficking within the Golgi apparatus, regulation of fibronectin translation, and 
interaction with lipid rafts to mediate apoptosis. We undertook an unbiased mass 
spectrometry approach to identify PfAtg8-binding proteins in the red blood cell stage of 
infection. Many exported proteins were identified, leading us to examine localization of 
PfAtg8 with exported proteins using immunofluorescence assays. Our studies suggest 
Atg8 is involved in trafficking proteins to the PV and host cytoplasm under basal 
conditions in the red blood cell. However these studies are preliminary and much work 




 As described in detail in Chapter 1, the function of Atg8 in Plasmodium is unclear 
and it is still under dispute if there is a bona fide autophagic pathway in Plasmodium. 
Strictly speaking, confirmation of macroautophagy in Plasmodium would require the 
presence of Atg8-labelled double-membrane vesicles, fusion of these vesicles with a 
lysosomal-like compartment, and breakdown and recycling of the autophagosome cargo. 
The strongest evidence is the recent report of Atg8 on double-membrane vesicles near 
and inside the acidic food vacuole upon starvation (66).  
 The unique biology of the parasite as well as the adaptability of the machinery in 
other organisms for non-autophagic purposes (191) makes alternative roles quite feasible 
and even likely. Kitmura et al. first described co-localization of PfAtg8 with the 
apicoplast markers histone-like protein, heat unstable (HU) and apicoplast localizing 
protein, (ACP) suggesting a hitherto unpredicted function distinct from autophagy (192). 
This co-localization does not appear to be complete, however (64, 66), and changes upon 
starvation or CQ treatment (66, 67). There is much work to be done determining the role 
of PfAtg8 in Plasmodium. This is complicated by the inability to knockout Plasmodium 
Atg8 and the difficulty in making conditional knockouts. PfAtg8 is lipidated (39) and the 
C-terminal glycine for lipidation is required for PfAtg8 localization (66). Therefore the 
Atg8 conjugation machine, including interaction with its conjugating enzyme, Atg3 is 
required for PfAtg8 localization and function. We attempted to use our Atg8 inhibitors, 
described in Chapter 3, as molecular probes to explore functions of PfAtg8 in the blood 
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stage. Together with results from our mass spectrometry-based PfAtg8 interactome study, 
we suggest a role for PfAtg8 in trafficking proteins to the host.  
 






Identification of PfAtg8 interactors  
 Atg8 homologues bind diverse proteins in other species to accomplish 
homologue-unique functions. We sought to identify PfAtg8 interacting proteins in order 
to gain insight into its function(s). PfAtg8 was immobilized via its hexahistidine tag and 
incubated with blood stage P. falciparum 3D7 protein lysate along with controls of either 
Ni-NTA resin or the unrelated Plasmodium proteins, PfGAP50 (PF3D7_0918000) and 
PfMTIP!60 (PF3D7_1246400) (193, 194). After extensive washing, His6-PfAtg8 and 
bound proteins were eluted and separated with SDS-PAGE (Figure 4.1A). Bands were 
cut out of Atg8 and control samples and analyzed with tandem mass spectrometry 
(MS/MS) (Figure 4.1B) by Dr. D. Colquhoun in the Graham laboratory (Johns Hopkins 
University, USA). In all replicates, peptides corresponding to endogenous PfAtg3, a 
known PfAtg8 interactor (Chapter 2, Figure 2.2), were identified in the PfAtg8 sample 
(Figure 4.1). In a reciprocal pulldown experiment, we immobilized PfAtg3 and incubated 
with parasite lysate. 13 unique peptides corresponding to Atg8 were identified with 78% 
coverage.  
 We segmented identified proteins from three PfAtg8 pulldown experiments into 
tiers according to their specificity for Atg8 and their repeated identification. Proteins 
identified in more than one replicate and in none of the controls were considered the 
strongest candidates in Tier 1A. Proteins appearing twice in the Atg8-immobilized 
sample and in one of the controls were considered Tier 1B. Proteins identified in the 
Atg8-immobilized sample in one experiment and in none of the controls were classified 
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as Tier 2. Tier 3 proteins were identified in one of the Atg8 samples with 100% 
probability and less than 30% probability in the controls (Table 4.1). Other proteins 
identified by MS/MS but not meeting these criteria are shown in Table A.4.  
 Four proteins were classified as tier 1A. Two of the four candidates, falcilysin 
(PF3D7_1360800) and m1-aminopeptidase (PF3D7_1472400), are located in the food 
vacuole and associated with hemoglobin degradation (195-198). Seven proteins were 
classified as tier 1B. Many chaperone proteins were present, including TCP-1 family 
proteins, 14-3-3I, and heat shock-family proteins. Chaperones were also present in the 
nonhits list, but not to the same extent (Table A.4). Ribosomal proteins and tRNA-
binding proteins were enriched in the Atg8 sample and were also prevalent in the non-hits 
list.  
 Figure 4.2 depicts the cellular location of candidates while figure 4.3 shows the 
biological processes represented and known interactions within them. A range of 
biological processes is represented, but protein translation and protein folding/trafficking 
are enriched. Hits were additionally arranged according to sub-cellular location, as 
indicated by the literature. Exported proteins, present at the parasite membrane, 
parasitopherous vacuole, trafficking organelle Maurer’s clefts (MC), and parasite 
membrane, are enriched. Among the exported proteins identified, the major virulence 
factor, PfEMP1 was identified in two independent experiments. PfEMP1 is exported to 
parasite-derived knob structures on the RBC surface. Though normally exported, these 
proteins were likely interacting with Atg8 within the parasite PM membranes, as infected 
red blood cells were saponin-treated to lyse the RBC (and PVM) membranes and washed 
with RPMI and PBS to remove erythrocytic cytoplasmic proteins.  
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Localization of endogenous PfAtg8 in blood stage 
 Because PfEMP1 was identified as a possible interacting partner in our mass 
spectrometry studies, we were interested to test if a pool of Atg8 co-localizes with 
PfEMP1 either inside the parasite or in the RBC cytoplasm. PfEMP1 is encoded by the 
multipcopy var gene family with ~60 variants, switching its expression regularly to evade 
host immunity (98, 199). Immuno-based studies against PfEMP1 are therefore difficult. 
However, only one Var member binds the placental receptor chondroitin sulfate A (CSA) 
(200, 201). By selecting for infected red blood cells (RBCs) that bind CSA, a parasite 
population is isolated that predominantly expresses Var2csa. P. falciparum FCR3-CSA 
parasites, kindly provided by Dr. J. Smith at Seattle BioMed, were exploited to examine 
localization of PfAtg8 and PfEMP1. 
 Because PfAtg8 was shown by several groups to localize to the apicoplast in 
blood and liver stages (38, 39, 66, 202), we first examined whether this was the case in 
our P. falciparum FCR3 CSA-selected strain. Using IFA, we observed co-localization 
between PfAtg8 and the apicoplast marker, ACP, throughout the blood stage (Figure 4.4).  
 Interestingly, when IFAs were conducted with parasites at a much higher 
parasitemia (26% rather than 5%) PfAtg8 did not co-localize with ACP and PfAtg8 was 
enriched at the parasite plasma membrane throughout the blood stage (Figure A.6). High 
parasitemia likely decreases the available nutrients compared to lower parasitemia culture 
conditions. Starvation has previously been shown to lead to re-localization of PfAtg8, to 
the RBC cytoplasm in one study (67) and to Rab7 vesicles and the food vacuole in 
another (66).  
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 We next tested whether PfAtg8 co-localized with PfEMP1 Var2csa under normal 
conditions. Although PfEMP1 could be detected outside the parasite, the signal was much 
higher within the parasite in our assays. Within, the parasite, PfAtg8 partially co-
localized with PfEMP1 (Figure 4.5). PfEMP1 is trafficked to the RBC membrane via the 
Maurer’s cleft and skeleton binding protein-1 (SBP1) a MC-localized protein, is required 
for PfEMP1 transport to the RBC surface (203, 204). We therefore sought to determine if 
PfAtg8 and PfSBP-1 (antibody kindly provided by Dr. C. Breton-Braun, Université 
Montpellier, France) co-localized under normal culture conditions. Using two different 
antibodies against either the amino end (BR5) or carboxy end (B28) of SBP1, we 
observed PfSBP-1 staining in the parasite as well as punctae in the RBC cytosol, 
consistent with the MC. Co-localization with PfAtg8 was again limited to a large pool of 
SBP-1 inside the parasite (Figure 4.6). Co-localization with both PfEMP1 and SBP-1 
persisted through the trophozoite and schizont blood stages.    
 
Inhibition of PfAtg8 with PAH9  (MMV007907) 
 Because a pool of PfAtg8 co-localized with the exported protein PfEMP1 and 
SBP-1, we hypothesized PfAtg8 might be involved in trafficking of PfEMP1. We treated 
cells with PAH9 for six hours and observed changes to PfAtg8 and PfEMP1 localization 
with immunofluorescence images. We did not observe any obvious changes to PfAtg8 
localization or co-localization with Var2csa at any stage (Figure A.7). However, it is 
possible that changes were too subtle to observe by eye. As mentioned previously, the 
signal of PfEMP1 in the RBC cytoplasm and surface was drastically lower compared to 
within the parasite. This may be an artifact of our fixation or staining procedure as RBC 
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structure appeared compromised in many cells. Therefore it was impossible to determine 
with IFA if drug treatment led to a decrease in PfEMP1 staining at the RBC surface. We 
therefore turned to flow cytometry to quantify PfEMP1 trafficking to the surface. 
 To quantify the amount of PfEMP1 on the surface of parasites, late rings were 
treated with PAH9 and PTA-D0 for 17 hrs.  Cells were stained with rabbit antiserum 
immunized against Var2csa or rabbit antiserum as a control. Cells were further stained 
with secondary antibody, DRAQ5 for sorting of iRBCs, and subjected to flow cytometry.  
84% of parasite-infected control cells were PfEMP1 positive (Figure 4.7A). The 
percentage of parasite-infected cells staining for PfEMP1 on the RBC surface decreased 
to 67.7% with 3 µM PAH9 and 46.8% with 30 µM PAH9 (Figure 4.7B,D). Similarly, 
64.2% of cells stained positive for PfEMP1 with 3 µM PTA-D0, however this decreased 
marginally with 30 µM treatment (Figure 4.7C,D). 3 µM drug treatment had no effect on 
the number of DRAQ5 positive cells. There was a 42% decrease in DRAQ5-positive cells 
with 30 µM PAH9 and 27% reduction with 30 µM PTA-D0, consistent with PAH9’s 




   
 Our MS/MS interactome study identified candidate PfAtg8-interacting proteins 
involved in a wide array of biological functions. Two known autophagy proteins were 
identitified, PfAtg3 (PF3D7_0905700.2) and cell division cycle protein 48 (Cdc48) 
homologue  (PF3D7_0619400), an AAA family ATPase necessary for autophagosome 
biogenesis in yeast and mammals (205, 206). We expected to find more autophagy 
proteins in our pulldown and were surprised by the absence of the E1-activiting enzyme, 
Atg7, as Atg7 is important for blood stage parasite growth (65).  
 
Represented biological processes: 
 Protein translation: Many ribosomal subunits and RNA-binding proteins critical 
for protein translation were identified, representing about 30% of the PfAtg8 hits. It is 
important to keep in mind that they represented 25% of nonhits. Ribosomal proteins are 
acidic in nature, while PfAtg8 is basic so these hits could represent nonspecific charge-
charge interactions. However the mammalian Atg8 homologue, LC3, regulates protein 
translation and stability of fibronectin through binding to an AU-rich element in the 
3’UTR (207, 208). 
 Chaperones: Chaperone family proteins constituted 13% of PfAtg8 candidates 
and 6% of non-hits. Chaperones are thought to play an important role in the Plasmodium 
parasite as it cycles between different temperatures and physiological conditions in the 
mosquito vector and human host, reviewed in (209). In addition to a cytoprotective role, 
it has been suggested that the Hsp70 family is involved in protein trafficking and export 
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(210). PfHsp70-3 (PF3D7_1134000) was a tier1B hit. PfHsp70-3 has been identified in 
the Maurer’s clefts (211, 212) and the parasitopherous vacuole (213). PfHsp70-3 
phylogenetically clusters with mitochondrial Hsp70 homologues, which drive 
translocation of proteins into the mitochondrial matrix (214) but also has high homology 
to human HspA9 (209), which is implicated in antigen export in humans (215, 216). 
Additionally, yeast-two hybrid studies with PfHsp70-3 identified many malarial exported 
proteins (data available on www.plasmodb.org).  
 In Chapter 3 we described an interesting effect on Hsp70 with drug treatment. 
Treatment of parasites with high levels of our inhibitor, PAH9, led to what appeared to be 
a cleavage of Hsp70 as well as accumulation (or induction of synthesis) (Figure 3.11). In 
mammals Hsp70 and its co-chaperone BAG3 deliver aggregates to p62 bodies, or 
aggresomes, in chaperone-assisted selective autophagy (CASA) (217). p62 is an 
autophagic receptor that recruits substrates to the autophagosome through interaction 
with the Atg8 homologue, LC3. Another chaperone identified in our study, 14-3-3 
(PF3D7_0818200) was recently elucidated as a major regulator in CASA through 
interaction with BAG3 (218).  
 Protein trafficking: A tier3 candidate, the small GTP-binding protein sar1 
(PF3D7_0416800) is a component of the COPII vesicle machinery for trafficking 
between the ER and Golgi. Sar1 was shown to have similar localization to the ER and 
small vesicle compartments in P. falciparum blood stages as in yeast, at the ER site for 
secretion of proteins (219, 220). m1-family aminopeptidase (PF3D7_1472400) was 
identified as a tier1B hit. It is implicated in hemoglobin degradation and has an 
interesting trafficking route first to the PV and then to food vacuole (197). The human 
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Atg8 homologues are involved in numerous vesicle trafficking pathways. For example, 
GATE-16 (Golgi-associated ATPase Enhancer of 16 kDa) is involved in intra-Golgi 
trafficking (221) and GABA (GABA(A) receptor-associated protein) is involved in 
GABAA receptor trafficking in neurons (222). Our study was enriched for proteins that 
are trafficked outside the parasite plasma membrane (Figure 4.2). Unconventional protein 
secretion, termed exophagy, utilizes the autophagosomal machinery as well as GRASP65 
and the t-SNARE, Sso1, which have putative homologues in Plasmodium (223, 224). 
Exophagy utilizes the COPII machinery but bypasses Golgi processing and is packaged 
into autophagosomes that fuse with plasma membrane (225). Double membrane vesicles 
have been observed with electron microscopy to fuse with the parasite plasma membrane 
(226). They were excluded as hemoglobin uptake by the lack of dense material and 
distance from the cytostome and suggested to be a form of exocytosis. 
 Chromatin remodeling and transcriptional regulation: Pfcasein kinase 2! 
(PfCK2!) differentially phosphorylated histone H2B in vitro as well as PfNapS (227), 
identified in our studies.  Human LC3 has been not only identified in the nucleoplasm, 
but is often enriched compared to soluble cytoplasmic LC3 (22, 228). Although generally 
there was no colocalization between PfAtg8 and DAPI in our IFAs, there was slight 
overlap in the ring stage (Figure 4.4). CK2 directly phosphorylate p62, which interacts 
with Ub and PfAtg8, to selectively degrade polyubiquitinated substrates (229). CK2 is 
suggested to modulate autophagic degradation of these protein aggregates. PfCK2! 
contains a putative AIM (Table 4.2) suggesting PfAtg8 may be a substrate for 
phosphorylation and could be a mechanism for regulation of plasmodial autophagy.  
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 Cdc48 is part of the ERAD complex. There is indirect evidence that Cdc48 is 
located at the apicoplast in Plasmodium and that the ERAD machinery has evolved into 
an import complex for the apicoplast (230).  
 
Role for PfAtg8 in PfEMP1 trafficking?  
 We identified PfEMP1 as a potential PfEMP1 interactor in our mass spectrometry 
study. Shortly after infection of erythrocytes, the P. falciparum begins to export hundreds 
of proteins to the host cell cytoplasm and membrane. Knob-like protrusions are formed 
on the RBC surface, displaying PfEMP1 to bind host cell molecules such as CD36, 
chondroitin sulfate A (CSA), and ICAM-1, on blood vessels. The iRBC adheres to the 
vasculature and evades clearance by the spleen. Sequestration of P. falciparum to 
endothelial cells lining the blood vessels is a major contributor to the mortality of malaria 
(231). Therefore, inhibition of parasite protein export is a viable strategy for antimalarial 
drug development (232).   
 In mammalian cells, Atg8 shows a cytosolic pattern of staining until induced by 
starvation when Atg8 redistributes to a more punctate pattern (30). In P. falciparum 
FCR3 parasites PfAtg8 shows a punctate pattern under non-starvation conditions. In 
addition to co-localization with ACP, considerable portion of PfAtg8 co-localizes with 
PfEMP1 within the parasite. SBP-1 also partially co-localizes with PfAtg8 within the 
parasite. SBP-1 is exported to the MC where it is involved in trafficking proteins to the 
RBC membrane. However SBP-1 does not contain the canonical export signal, PEXEL 
motif, used by many Plasmodium proteins to be exported past the PVM. Potentially, 
PfAtg8 is involved in targeting and trafficking SBP-1 and PfEMP1 from the ER. If so, it 
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is unclear if Atg8 remains attached to these vesicles beyond the parasite PM, and the 
PVM, as some researchers observe PfAtg8 in the parasite cytoplasm under starvation 
conditions and to a lesser degree under homeostasis (69).  
 Although we could not detect a change in PfEMP1 staining with IFAs under 
PAH9 treatment, the number of cells examined was limited to ten. FACS allowed us to 
examine 10,000 infected cells quickly. These preliminary studies showed a decrease in 
PfEMP1 surface staining with inhibition of the PfAtg8-PfAtg3 interaction. The effect was 
subtle with 3 µM PAH9 treatment, with a 16% reduction in PfEMP1 positive iRBCs. 
Therefore it is not surprising that we could not visually detect a difference with IFAs 
when a similar concentration of PAH9 was used with a much shorter treatment period of 
six hours compared to seventeen. Although the effect on PfEMP1 surface expression is 
exciting, it is important to note that it is unknown if PfAtg8 is directly involved in 
PfEMP1 export. It is plausible that the toxicity of the drugs leads to a global decrease in 
export as the parasite tries to conserve resources. We also need to confirm that the 
decrease in PfEMP1 staining is due to a decrease in trafficking and not protein synthesis. 
In the future, we will detect overall levels of PfEMP1 with flow cytometry on fixed and 
permeabilized cells and with immunoblotting. Additionally, a stable GFP-expressing line 
will allow us to determine if protein synthesis is decreased with PAH9 treatment. 
 It is also plausible that the drug phenotype is due to off-target effects. However, 
our FACS, IFA, and mass spectrometry-based interactome studies together provide 
intriguing evidence that Atg8 is involved in PfEMP1 trafficking and warrants further 
study to verify and elucidate the mechanism.  PfEMP1 is a major contributor to the 
virulence and death caused by P. falciparum, leading to sequestration of infected red 
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blood cells as well as clumping of infected and uninfected RBCs. Hundreds of proteins 
are exported and essential for parasite survival. Targeting trafficking of the hundreds of 
exported parasite proteins is an appealing strategy for antimalarial drug design.  
 
Future Directions 
 We have begun to test our candidates for a direct interaction with PfAtg8. In our 
mass spectrometry experiment, we identified peptides corresponding to PfAtg8 in our 
MTIP!60 and GAP50 controls, but not in the resin only control. SPR studies with 
recombinant PfAtg8 and MTIP!60 confirmed direct binding but the physiological 
relevance of this interaction is unknown. It is possible that this interaction confounded 
our studies, leading to more false negatives. GAP50 was used as a control in one replicate 
and would be a better control for future studies as it is similarly basic like PfAtg8. 
Additionally, reports of exported PfAtg8 indicate that there may be potential PfAtg8 
interactors missed in our study due to saponin lysis and removal of the RBC cytoplasm 
and PV.  
 Parasites grown to high parsitemia, likely leading to starvation conditions show 
very little co-localization between PfAtg8 and ACP. PfAtg8 appears to be enriched at the 
plasma membrane. It would be interesting to examine PfAtg8 co-localization with 
exported proteins under these conditions. One question is whether depriving parasites of 
amino acids and other nurtients is physiological? However the standard technique for 
culturing parasites, using supplemented RPMI 1640 has supraphysiological levels of 
nutrients two to greater than four times the level found in human plasma (233). An 
interesting experiment would be to look at Atg8 localization in mice either well fed or 
malnourished; global incidence of malnourishment and malaria overlap. In support of this, 
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it was reported this year that the necessity of certain drug targets differs under in vitro 
culture conditions and in vivo (233).  
  PfEMP1 was identified as a candidate PfAtg8-binding protein. We searched 
PlasmoDB for PfEMP1 variants carrying putative AIMs. While 14 of 107 PfEMP1 
annotations contained our newly identified WXXP motif, 80 contained the more 
canonical motif, present in mammals and yeast, WXXL. This was expanded to 86 if 
alternative AIM WXXI is included. The sequence of the motif was most commonly 
WNTL or WNQ/EL and is located approximately 120 amino acids into the acidic 
intracellular terminal segment (ATS), semi-conserved among var genes (Figure A.8). The 
ATS of PfEMP1 binds numerous proteins, including SERA5, another candidate in our 
study, through its ATS (234). In the future we will test direct binding of this region to 
PfAtg8. As PfEMP1 does not contain an N-terminal signal peptide sequence for entering 
the ER secretory pathway and lacks a canonical PEXEL motif for export, binding to 
PfAtg8 could play a role in PfEMP1 trafficking. In support of this, the ATS is important 
for trafficking of PfEMP1 to the Maurer’s clefts, though in studies using chimeras of 
PfEMP1 transmembrane domain (TM) and ATS truncations fused to the N-terminal 
region of KHARP indicate only the first 113 amino acids of the ATS is required for MC 
localization (235).  




Methods & Materials 
 
Parasite harvestation: Plasmodium-infected red blood cells (RBCs) were pelleted with 
centrifugation at 500 x g, 25ºC and washed twice with 37C RPMI. RBCs were lysed 
with 0.2% saponin in PBS (1.06 mM KH2PO4, 5.6 mM Na2HPO4, 154 mM NaCl, pH 
7.4) followed by centrifugation at 5000 x g, 4ºC. The parasite pellet washed with PBS 
and resuspended in PBS with 1x Complete EDTA-free protease inhibitor (Roche) and 
sonicated on ice for 5-30 sec pulses, output power 15%. Lysate was centrifuged for 20 
min at 3000 x g.    
 
Identification of PfAtg8 endogenous binding partners: PfAtg8 was immobilized via 
its hexahistidine tag to a Ni-NTA column. 50 mLs of asynchronous P. falciparum 3D7 
blood stage culture (predominantly trophozoites) (2% hematocrit, 5-7.5% parasitemia) 
was harvested, lysed, and equal amounts of supernatant was incubated with Ni-NTA 
columns (Qiagen) with immobilized His6-PfAtg8 or various controls for nonspecific 
binding (resin only, His6-PfGAP50, or His6-PfMTIP!60 (193, 236). The columns were 
washed with 1x PBS. Bound proteins were eluted in wash buffer containing 50 mM 
HEPES pH 7.4, 300 mM imidazole, 10% glycerol, fractionated with SDS-PAGE, and 
visualized using SYPRO® Ruby stain (Invitrogen) using a typhoon 9410 scanner (GE 
Healthcare).  
 
Mass spectrometry analysis: Gel bands were excised, washed, and reduced with 10 mM 
DTT in 20 mM NH4HCO3 for 1 hr at 56°C, and alkylated in 55 mM iodoacetamide in 20 
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mM NH4HCO3 in the dark at RT, 45 min. Finally, digestion was conducted with 25 µL of 
10 ng/µL proteomics-grade trypsin in 20 mM NH4HCO3 (Promega) overnight. Digests 
were extracted, concentrated, and injected onto an Agilent 6520 Q-TOF with a Chip 
Cube interface with standard gradients. Acquisition parameters were previously 
published (237). The Mascot Daemon search tool (Matrix Science) was used to process 
acquired spectra and search against the NCBI subset databases (238, 239). Results were 
visualized in Scaffold 2.0 (Proteomics Software). Proteins with at least two matched 
peptides above the significance threshold (minimum peptide ID probability of 90% and 
minimum protein ID probability of 99%) were categorized as either a tier 1-3 hit or a 
non-hit for PfAtg8 interaction. Categorization is specified in results section.   
 
Cell culture: P. falciparum strain FCR3-CSA selected on chondroitin sulfate A was 
kindly provided by Dr. J. Smith, Seattle BioMed, USA. 
 
Antibodies and antiserum: Rabbit !IT4-DBL3-Var2CSA antiserum (1:25) was kindly 
provided by Dr. J Smith, Seattle BioMed, USA. Mouse monoclonal antibody against 
TgAtg8 peptide (1:100) and affinity-purified rabbit antisera against TgAtg8 (1:250) were 
kindly donated by Dr. P. Roepe, Georgetown University, D.C, USA (69). Rat !-ACP 
(1:2000) (kindly provided by Dr. S. Prigge, Johns Hopkins University, USA). Rabbit 
!BR5 (against the N-terminus of PfSPB-1, 1:200) and rabbit !B28 (against PfSPB-1, 
1:200) were kindly donated by Dr. C. Braun-Breton, Université Montpellier, France. 
Goat !Rabbit IgG Alexa fluor 594 (1:3000), goat !Rat Alexa fluor 488 (1:500), and goat 
!Mouse IgG Alexa fluor 488 (1:2000) purchased from Invitrogen.  
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Immunofluorescence: All steps were carried out at 25ºC unless otherwise stated. Cells at 
5% parasitemia (unless otherwise stated), 2% hematocrit, were harvested by 
centrifugation and the cell pellet washed with PBS. Cells were fixed in PBS containing 
4% formaldehyde and 0.0075% glutaraldehyde and incubated on polylysine-treated slides 
for 30 min. Cells were permeabilized with 0.1% Triton-X-100 for 10 min, washed with 
PBS, the aldehydes reduced by incubation with 0.1 mg mL-1 NaBH4 for 10 min, washed 
with PBS, and blocked in 3% bovine serum albumin (BSA) in PBS for 1 hour. Cells were 
incubated with primary antibodies diluted in 3% BSA in PBS overnight at 4ºC. Cells 
were washed with PBS three times, incubated with appropriate secondary antibody (in 
3% BSA in PBS) 1 hr and washed four times with PBS. Slides were treated with Prolong 
Gold anti-fade reagent with DAPI (Invitrogen). By the way, if you have read this far, you 
deserve a bottle of wine at my thesis defense. Images (10 per condition) were taken on a 
Nikon Eclipse 90i with z-stack slices of 0.2 µm, spanning approximately 4 µm and 
deconvolved using VOLOCITY software.  
 
IFA of PAH9-treated culture: P. falciparum FCR3CSA at 1.6% parasitemia, 2% 
hematocrit in complete media were treated with 5 µM PAH9 or equivalent (0.1% w/v) 
DMSO for six hours.  
 
Flow cytometry: All steps conducted at 25ºC. P. falciparum FCR3 CSA-selected 
parasites were treated with 1:25 Rb !Var2csa antiserum (kindly provided by Dr. J Smith, 
Seattle BioMed, USA) or rabbit non-immune antiserum (kindly provided by Dr. J. 
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Levitskaya, Johns Hopkins University, USA) diluted in 1x PBS, 3% BSA for 30 min, 
washed three times with 1x PBS, and stained with Alexa Fluor 488 !Rabbit IgG for 30 
min (Molecular Probes). Cells were washed three times 1x PBS and DRAQ5 was used at 
1:5000 in 1x PBS. Approximately 1 million cells were analyzed for side and forward 
scatter with the FACScalibur flow cytometer (BD Biosciences) and gated to remove 
doublets or dead cells. Gated cells were further gaited for DRAQ5 fluorescence to 
indicate infected RBCs. The number of infected cells expressing Var2csa was measured. 
PfEMP1 positive gate was determined by comparison to an isotype control. Analysis and 





Table 4.1. Candidate PfAtg8-interacting proteins from mass spectrometry-based interactome study. 
Proteins were identified with mass spectrometry. Experiment was repeated three times with different 
controls: Ni-NTA resin, PfGAP50, or PfMTIP!60. The percent probability of correct identification is 
indicated for each sample (0% indicates not identified). Tier 1A hits have proteins identified in PfAtg8 
sample in multiple experiments but none in controls (PfAtg3 was not considered a control since interactions 
with PfAtg8 can be mediated through PfAtg3 and vice versa). Tier 1B hits have multiple identifications in 
PfAtg8 but were also identified in some controls. Tier 2 hits have identification in one experiment in 
PfAtg8 but none in controls. Tier 3 hits were identified in one experiment of PfAtg8 with 100% probability 
and less than 30% probability in control.  







Identified Proteins (RecName) GI number MW  R2 R3 R1 R2 R3 R1 R3 R2 R3
chaperone, putative gi|86170750 PF3D7_0608700 62 kDa 0 0 0 100% 25% 0 0 0 0
falcilysin gi|124513926 PF3D7_1360800 139 kDa 50% 0 93% 100% 0 0 0 0 0
insulinase, putative gi|124803959 PF3D7_1118300 174 kDa 0 0 0 100% 21% 0 0 0 0
m1-family aminopeptidase gi|124512980 PF3D7_1472400 126 kDa 100% 25% 0 100% 49% 0 0 0 0
14-3-3 protein (14-3-3I) gi|124512420 PF3D7_0818200 29 kDa 0 24% 100% 100% 75% 0 75% 100% 0
60S ribosomal subunit protein L18 gi|124513556 PF3D7_1341200 22 kDa 0 0 0 100% 28% 100% 0 0 0
Actin-1 gi|113224 PF3D7_1246200 42 kDa 0 0 100% 100% 0 0 0 100% 0
casein kinase II, alpha subunit gi|124803615 PF3D7_1108400 40 kDa 7% 57% 0 100% 75% 0 41% 0 78%
heat shock protein hsp70 homologue (Pfhsp70-3) gi|11127605 PF3D7_1134000 72 kDa 0 22% 0 100% 18% 0 0 0 97%
histone H2B gi|124803500 PF3D7_1105100 13 kDa 0 74% 0 83% 75% 0 100% 0 0
40S ribosomal protein S8e, putative gi|124808201 PF3D7_1408600 25 kDa 0 0 0 100% 0 0 0 0 0
6-phosphofructokinase gi|124506857 PF3D7_0915400 159 kDa 0 0 0 100% 0 0 0 0 0
60S ribosomal protein L1, putative gi|124809402 PF3D7_1441200 25 kDa 0 0 0 100% 0 0 0 0 0
60S ribosomal protein L5, putative gi|124808771 PF3D7_1424100 34 kDa 0 0 0 100% 0 0 0 0 0
60S ribosomal protein P0 gi|124804377 PF3D7_1130200 35 kDa 0 0 0 100% 0 0 0 0 0
60S ribosomal subunit protein L4/L1 gi|124506063 PF3D7_0507100 46 kDa 0 0 0 100% 0 0 0 0 0
60S ribosomal subunit protein L6e gi|124513506 PF3D7_1338200 26 kDa 0 0 0 100% 0 0 0 0 0
arginine methyltransferase 1 (PRMT1) gi|124808818 PF3D7_1426200 47 kDa 0 17% 0 100% 0 0 0 0 0
cell division cycle protein 48 homologue gi|296004694 PF3D7_0619400 90 kDa 0 0 0 100% 0 0 0 0 0
conserved Plasmodium protein, unknown function gi|124506449 PF3D7_0526600 525 kDa 0 100% 0 0 100% 0 0 0 0
cysteinyl-tRNA synthetase, putative gi|258597035 PF3D7_1015200.1 79 kDa 0 0 0 100% 0 0 0 0 0
Cytoadherence linked asexual protein, CLAG gi|124504715 PF3D7_0302500 167 kDa 83% 0 0 100% 0 0 0 0 0
DNA/RNA-binding protein Alba 4 (ALBA4) gi|124513666 PF3D7_1347500 42 kDa 0 0 0 100% 0 0 0 0 0
endoplasmic reticulum-resident calcium binding 
protein (ERC) gi|124803623 PF3D7_1108600 39 kDa 0 0 0 100% 0 0 0 0 0
erythrocyte membrane protein 1, PfEMP1 (VAR) gi|914919 PF3D7_1200400 336 kDa 0 0 100% 0 0 0 0 0 0
erythrocyte membrane protein 1, PfEMP1 (VAR) gi|258597176 PF3D7_1041300 251 kDa 0 0 0 0 100% 0 0 0 0
ethanolamine kinase gi|124804188 PF3D7_1124600 50 kDa 0 0 0 100% 0 0 0 0 0
eukaryotic translation initiation factor 2 alpha 
subunit gi|124512088 PF3D7_0728000 38 kDa 0 0 0 100% 0 0 0 0 0
fructose-bisphosphate aldolase (FBPA) gi|3319034 PF3D7_1444800 40 kDa 0 0 0 100% 61% 0 0 100% 0
glutamine synthetase, putative gi|124507000 PF3D7_0922600 50 kDa 0 0 0 100% 0 0 0 0 0
heat shock protein 110 (HSP110c) gi|124511738 PF3D7_0708800 100 kDa 0 0 0 100% 0 0 0 0 0
high molecular weight rhoptry protein 3 (RhopH3) gi|124506661 PF3D7_0905400 105 kDa 100% 73% 0 100% 0 0 0 0 0
high molecular weight rhoptry protein-2 gi|27414156 PF3D7_0929400 163 kDa 100% 0 0 100% 0 0 0 0 0
isoleucine-tRNA ligase gi|124513408 PF3D7_1332900 151 kDa 0 0 0 100% 0 0 0 0 0
karyopherin beta gi|124506397 PF3D7_0524000 127 kDa 100% 0 0 100% 0 0 0 0 0
lysine-tRNA ligase gi|124513716 PF3D7_1350100 68 kDa 0 0 0 100% 0 0 0 0 0
methionine-tRNA ligase, putative gi|124802884 PF3D7_1034900 104 kDa 0 0 0 100% 0 0 0 0 0
nucleosome assembly protein (NapS) gi|114280 PF3D7_0919000 30 kDa 0 0 0 100% 0 0 0 0 0
parasite-infected erythrocyte surface protein 
(PIESP1) gi|124504869 PF3D7_0310400 154 kDa 0 0 0 100% 0 0 0 0 0
plasmepsin III,histo-aspartic protease (HAP) gi|124808181 PF3D7_1408100 52 kDa 0 0 0 100% 0 0 0 0 0
QF122 antigen gi|124802200 PF3D7_1011800 132 kDa 0 0 0 100% 0 0 0 0 0
ribosomal protein L17 gi|124513742 PF3D7_1351400 23 kDa 0 0 0 100% 0 0 0 0 0
ribosomal protein L6 homologue gi|124513230 PF3D7_1323100 22 kDa 0 0 0 100% 0 0 0 0 0
ribosomal protein S19s gi|124505571 PF3D7_0422400 20 kDa 0 0 0 100% 0 0 0 0 0
ribosomal protein S2 gi|124809606 PF3D7_1447000 30 kDa 0 0 0 100% 0 0 0 0 0
serine-repeat antigen 5 protein gi|7158837 PF3D7_0207600 112 kDa 100% 0 0 100% 0 0 0 0 0
T-complex protein 1 epsilon subunit gi|124505063 PF3D7_0320300 59 kDa 0 0 0 100% 0 0 0 0 0
T-complex protein beta subunit gi|124504803 PF3D7_0306800 59 kDa 0 0 0 100% 0 0 0 0 0
TCP-1/cpn60 chaperonin family, putative gi|124504829 PF3D7_0308200 60 kDa 0 0 0 100% 0 0 0 0 0
threonine-tRNA ligase, putative gi|124804231 PF3D7_1126000 120 kDa 0 0 0 100% 0 0 0 0 0
tRNA binding protein, putative gi|124809439 PF3D7_1442300 46 kDa 0 0 0 100% 0 0 0 0 0
vacuolar ATP synthase subunit a (vapA) gi|124512982 PF3D7_1311900 69 kDa 0 0 0 100% 0 0 0 0 0
valine-tRNA ligase, putative gi|124810112 PF3D7_1461900 128 kDa 0 0 0 100% 0 0 0 0 0
Tier 3
40S ribosomal protein S3, putative gi|124810210 PF3D7_1465900 25 kDa 0 0 0 100% 0 0 0 0 18%
conserved Plasmodium membrane protein, 
unknown function gi|124512678 PF3D7_0804500 706 kDa 0 0 0 0 100% 0 15% 0 0
heat shock protein 90, putative gi|124803955 PF3D7_1118200 108 kDa 0 72% 0 100% 0 0 15% 0 0
small GTP-binding protein sar1 gi|124505467 PF3D7_0416800 22 kDa 0 0 100% 0 0 28% 0 0 0
microtubule-associated protein 1 light chain 3 gi|124802463 PF3D7_1019900 15 kDa 100% 100% 100% 100% 100% 0 100% 100% 0
autophagy-related protein 3, putative (ATG3) gi|296005163 PF3D7_0905700.2 37 kDa 100% 100% 100% 100% 100% 0 75% 100% 100%
secreted acid phosphatase (GAP50) gi|124506908 PF3D7_0918000 45 kDa 0 0 0 0 0 0 100% 0 0



























Table 4.2. Putative AIMs in candidate PfAtg8 interacting proteins.  AIM sequence and amino acid 




Protein PlasmoDB code   AIM sequence 
Atg3 PF3D7_0905700.2    104  WLLP  108 
RhopH3 PF3D7_0905400    312  WNVP  315 
NAPS PF3D7_0919000    209  WHNP  212 
threonine-tRNA ligase, putative PF3D7_1126000    897  WLSP  900 














Figure 4.1. PfAtg8 interacts with endogenous PfAtg3 in the blood stage. A. Parasite lysate pulldown 
assay. His6-PfAtg8 was attached to Ni–NTA resin and incubated with RBC stage P. falciparum lysate. 
Bound proteins were subjected to SDS–PAGE and visualized with SYPRO® Ruby staining. Asterisk 
denotes band in which PfAtg3 peptides were identified through MS/MS. B. Top: MS/MS spectra from 2 
unique PfAtg3 peptides identified in PfAtg8WT bait sample, not identified in control, searched against the 
NCBI database with Mascot. Bottom: Coverage of Atg3 sequence by 2 unique peptides identified with 92% 




Figure 4.2. Sub-cellular location of PfAtg8-interacting candidate proteins. PfAtg8-interacting 
candidates are listed according to sub-cellular compartment in trophozoite-stage parasite inside RBC (57, 








Figure 4.3. Biological function of PfAtg8-interacting candidate proteins. Interactions within candidates 
are depicted with lines. Solid lines indicate identification through Y2H assay on plasmodial proteins while 














Figure 4.4. PfAtg8 co-localizes with apicoplast protein, ACP in blood stages. Antibodies specific for 
the apicoplast marker ACP were used to visualize the apicoplast in the FCR3 CSA-selected parasite line. 
Antibodies against TgAtg8 cross react with PfAtg8 (69) and show partial co-localization with PfAtg8 and 
ACP in the ring, trophozoite, and schizont stage (from top to bottom). Image z-stacks were deconvolved 













Figure 4.5. PfAtg8 co-localizes with exported virulence factor PfEMP1 in blood stage parasites. P. 
falciparum strain FCR3 CSA-selected parasites were fixed and stained antibodies against a TgAtg8 peptide 
(cross-reactive with PfAtg8 (69)) and Var2CSA in late ring, early and late trophozoite, and schizont stages 






Figure 4.6. Partial co-localization of PfAtg8 with maurer’s cleft protein, SBP-1 within blood stage 
parasites. IFAs were used to examine co-localization of PfAtg8 and maurer’s cleft protein, SPB-1, in early 
trophozoite to early schizont blood stages (top to bottom) of P. falciparum FCR3 selected for binding to 
CSA. Endogenous Atg8 was detected with anti-TgAtg8 peptide antibodies cross-reactive to PfAtg8 (69). 
Two antibodies against the C-terminal, BR5 in A and N-terminal in B of SBP-1 were tested. Image z-stacks 










Figure 4.7. PfAtg8-PfAtg3 inhibitors decrease PfEMP1 staining on RBC surface. A. Histogram of 
infected RBCs for var2csa staining levels. DMSO control cells shown in gray with isotype secondary 
control negative for var2sca staining. Gate for var2csa shown in black with percentage of cell population 
within that gate shown above. B. PAH9-treated cells shown in black with DMSO-treated control in gray. C. 
PTA-D0-treated cells shown in black with DMSO-treated control cells in gray. D. Bar graph showing 
















 We elucidated the interaction between PfAtg8 and its E2-conjugating enzyme, 
PfAtg3 through X-ray crystallography and biochemical assays. The A-loop, unique to 
Plasmodium and other Apicomplexans was found to be vital to the interaction with 
PfAtg3. We additionally confirmed that a similar Atg8-interacting motif present in yeast 
and mammalian species is involved in binding. However we show the motif uses a 
previously unidentified variation where leucine or isoleucine is replaced by proline. It is 
likely that other plasmodial Atg8-interacting proteins utilize a similar motif, laying the 
groundwork for identification of novel binding partners. A search within plasmoDB 
yields 455 P. falciparum genes containing the WXXP motif, including Atg7 
(PF3D7_1133400), Atg4 (PF3D7_1417300), and PI3K (PF3D7_1133400). In Chapter 1, 
we described bioinformatic identification of many of the Atg homologues in Plasmodium 
(Figure 1.3). The expression of these putative homologues overlaps in the ring and 
trophozoite blood stages (Figure 1.4). PfAtg8 co-localization with Rab7 on DMV near 
and within the food vacuole under starvation (66) strongly suggests that autophagy is 
conserved in Plasmodium. However, the origin of the engulfed material, endocytosis of 
host material or parasitic, has not been determined.  
 In chapter 3 we detail the identification of inhibitors against the PfAtg8-PfAtg3 
interaction with activity against blood and liver stages. These could serve as molecular 
tools to understand PfAtg8’s essential function. We began preliminary studies using one 
of the inhibitors, PAH9, described in chapter 4. It was surprising that 5 µM PAH9 did not 
have a noticeable effect on PfAtg8 localization in IFAs. We saw drastic accumulation of 
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PfAtg8 protein levels with 50 µM levels (chapter 3). In the future, it will be necessary to 
confirm delipidation of PfAtg8 upon drug treatment and to determine the concentration 
necessary to prevent lipidation in cell culture for PAH9 and C25 to be useful probes for 
PfAtg8 function. We are simultaneously pursuing optimization of our hits for therapeutic 
use as antimalarial drugs. 
 
Current Model for Atg8 Function 
 
 Based on our preliminary findings and previous research in the field, presented in 
chapter 1, our model for the role of PfAtg8 in the blood stage is depicted in figure 5.1. 
During basal blood stage growth, the autophagy machinery including Atg8 and a pool of 
PfPI3K is localized to the apicoplast where it traffics proteins or lipids to the apicoplast 
and later recruits proteins or lipids for increased growth in preparation for cellular 
division. This does not require induction and occurs both in the liver and blood stage and 
most likely in the oocyst and sporozoite mosquito stages as well. A pool of PfAg8 is also 
involved in trafficking proteins destined for the Maurer’s clefts from the ER.  
 Under cases of cellular starvation, the parasite induces a pathway using the 
autophagy machinery that increases endocytosis of host cytoplasm and digestion in the 
food vacuole. Atg8 may or may not be present on vesicles outside the parasite. Starvation 
may alternatively or additionally induce a bona fide autophagy pathway, where parasitic-
derived proteins and material are enclosed within autophagosomes that fuse with Rab7 
endosomes and are degraded within the food vacuole.  
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 Under drug treatment or extreme stress from which the parasite cannot recover, 
the balance may be tipped to autophagic death. This may also be a mechanism to limit the 
number of parasites in the liver stage such that only the most robust parasites continue to 
the blood stage of infection. What little evidence exists suggests this cell death is 




 Remarkable progress has been made in the last year, dissecting the role of the 
autophagic machinery in Plasmodium, but many questions remain. The field is in 
agreement that Atg8 at least partially localizes to the apicoplast, but is it essential to 
maintain the organelle? Does Atg8 transport proteins, phospholipids, or both to the 
apicoplast? How is it targeted to the apicoplast specifically?   
 Although Tomlins et al. (66) observe Atg8 in the food vacuole; it is unclear if 
PfAtg8 is trafficking hemoglobin or endogenous protein. Immunofluorescence, co-
staining for anti-hemoglobin antiserum and anti-Atg8 antibodies, would elucidate 
whether PfAtg8 is involved in trafficking of hemoglobin. Mature red blood cells no 
longer synthesize new proteins. Therefore time-course radiolabelling experiments could 
determine if PfAtg8 was involved in trafficking endogenous parasite proteins. Following 
a time course would reveal the final destination of these vesicles: the food vacuole, 
apicoplast, or parasite PM.  
 Due to the differences in P. falciparum strain sensitivity to CQ and different 
effects observed with varying concentrations and exposure times, amino acid deprivation, 
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the canonical inducer of autophagy, is a more suitable tool to study this pathway in 
Plasmodium. Still, even under starvation conditions, different researchers describe 
distinctive effects. Possible reasons for this difference are the antibodies used to detect 
endogenous PfAtg8. It would be of great use to compare antibodies used by Tomlins et 
al., Kitamura et al. and Roepe et al. (39, 66, 67) on the same population of cells to 
determine if differences are attributable to antibody specificity, strain, or culture 
conditions used. 
 In contrast to specifically omitting nutrients, I examined PfAtg8 localization 
under high parasitemia conditions, increasing competition for nutrients. PfAtg8 was 
enriched along the parasite plasma membrane, and could represent endocytic vesicles. 
This effect was unexpected by us and has not been further examined. High parasitemia 
conditions may be more physiologically relevant than the use of incomplete media, but 
the perturbation of more than one factor will complicate studies into the underlying 
mechanism. For example, it has recently been shown that microvesicles allow for 
parasite-parasite communication within a population (251). 
 If autophagy is conserved within Plasmodium, a larger question is what acts 
upstream of the putative PfAtg1 to induce autophagy under starvation conditions as TOR 
homologues appear to be absent. In yeast, cAMP-dependent protein kinase (PKA) 
signaling regulates Atg1 independent from TOR and may be a regulator in Plasmodium 
(252). PfVps34 is phosphorylated in the parasite at a predicted PKA site (253). PfeIK1, 
an orthologue for eukaryotic initiation factor 2! kinase, has been implicated in the amino 
acid starvation response in Plasmodium and has been suggested as a possible mediator of 
autophagy induction (67, 254).  Its substrate, eIF2! (PF3D7_0728000), was identified as 
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a candidate in our mass spectrometry-based PfAtg8 pulldown study. Knockout (KO) of 
PfeIK1 abolishes starvation-induced phosphorylation of eIF2! in P. falciparum blood 
stage cultures (254). Would PfAtg8 re-localize with starvation or high parasitemia 
conditions in PfeIK1 KO cells? PfeIK1 knockout did not affect growth of blood stages, 
under normal conditions, but what about under starvation? Would our PfAtg8-PfAtg3 
inhibitors have greater efficacy against this line?  
 
Public Health Implications 
 
 Malaria continues to present a global public health problem, killing over half a 
million people each year. Our studies suggest PfAtg8 may be involved in trafficking 
PfEMP1. PfEMP1 is major virulence factor that binds host endothelium, sequestering 
infected RBCs and contributing to death in cerebral malaria and complications and 
mortality in pregnancy (255, 256). It’s trafficking to MCs in the RBC cytoplasm and 
from the MC to the RBC surface is under extensive study (257). Host cell remodeling, 
via the export of parasite proteins, is necessary for parasite virulence, therefore presenting 
an attractive candidate for antimalarial drug design. In the future, we will confirm that 
inhibition of PfAtg8-PfAtg3 specifically inhibits transport of PfEMP1 to the surface. At 
this time, there are more questions than answers, but it is encouraging to see that the field 









Figure 5.1. Model for PfAtg8 function in the trophozoite stage. Function in normal cell conditions 
displayed with black arrows and stress/starvation conditions are shown with red arrow. 1. Secretion of 
proteins from the ER and trafficking from the Golgi to the parasite PM. 2. Golgi-independent secretion of 
DMVs from the ER to the parasite PM. 3. Trafficking of proteins or lipids to the apicoplast. 4. Endocytosis 
of hemoglobin or host nutrients under starvation. 5. Macroautophagy of parasite proteins with degradation 















Table A.1. Identity and blast information for P. falciparum Atg8 orthologues. Atg autophagy-related 
proteins from yeast, humans, or other species were queried against PlasmoDB. Information of the putative 
homologue is included. Likely homologues are colored in green (e-value less than 1e-10 in initial BLAST 
within PlasmoDB and reciprocal identification using PSI-BLAST with e-value less than 1e-20). Gray 
indicates homology less clear (initial e-value cutoff of 0.012 and identification of initial query in either PSI- 











TOR1 S. cerevisiae PF3D7_0419900 0.0018 Yes phosphatidylinositol 4-kinase, putative
Induction
Atg1 A. thaliana PF3D7_1450000 1.60E-35 Not all serine/threonine protein kinase, putative
FIP200 (Atg17 
homologue) H. sapiens PF3D7_0504700 2.60E-23 Yes conserved Plasmodium protein, unknown function 
Atg101 D. rerio PF3D7_1444600 0.053 Not all conserved Plasmodium protein, unknown function
Nucleation
Vps34 S. cerevisiae PF3D7_0515300 1.90E-84 Yes phosphatidylinositol 3-kinase (PI3K)
Vps15 H. sapiens PF3D7_0823000 5.10E-11 Yes protein kinase , putative
Atg14 P. troglodytes PF3D7_1220800 0.0014 Yes conserved Plasmodium protein, unknown function 
Atg9 cycling
Atg2 S. cerevisiae Pf3D7_1320000 0.0034 Yes rhoptry protein 2, putative (PRP2) 
Atg18 S. cerevisiae PF3D7_1012900 1.90E-17 Yes conserved Plasmodium protein, unknown function
Atg9 S. cerevisiae PF3D7_0607700 3.30E-10 yes conserved Plasmodium protein, unknown function 
Maturation
Atg4 S. cerevisiae PF3D7_1417300 4.90E-09 Yes cysteine protease ATG4, putative (ATG4) 
Atg8 S. cerevisiae PF3D7_1019900 3.10E-24 Yes autophagy-related protein 8, putative (ATG8)
Atg3 S. cerevisiae PF3D7_0905700.1 6.30E-23 Yes autophagy-related protein 3, putative (ATG3) 
Atg7 S. cerevisiae PF3D7_1126100 4.00E-51 Yes autophagy-related protein 7, putative (ATG7) 
Atg12 S. cerevisiae PF3D7_1470000 3.50E-09 Yes autophagy-related protein 12, putative (ATG12) 
Atg16 H. sapiens PF3D7_1406500 0.0079 Yes conserved Plasmodium protein, unknown function 
Atg5 H. sapiens PF3D7_1430400 1.30E-06 Yes conserved Plasmodium protein, unknown function 
Fusion
Rab7 S. cerevisiae PF3D7_0903200 3.10E-63 Yes Rab GTPase 7 (Rab7) 
Vam3 S. cerevisiae PF3D7_1104100 5.30E-09 Yes syntaxin, Qa-SNARE family (SYN13) 
Atg22 S. cerevisiae PF3D7_0206200 0.012 Yes metabolite/drug transporter, putative 
Vps39 S. cerevisiae PF3D7_1423800 9.40E-05 Yes conserved Plasmodium protein, unknown function 
Sec22 S. cerevisiae PF3D7_0320100 4.60E-23 Yes Sec22
VAMP8 H. sapiens PF3D7_1303200.1 7.20E-10 Yes SNARE protein, putative (VAMP8) 
AtVti1b A. thaliana Pf3d7_1236000 1.30E-07 Yes conserved Plasmodium protein, unknown function 
Ykt6 S. cerevisiae PF3D7_1324700 7.30E-32 Yes SNARE protein, putative (YKT6.2)
Exophagy
GRASP65 S. cerevisiae PF3D7_1017300.1 2.80E-25 Yes golgi re-assembly stacking protein 1 (GRASP1) 
Sso1 S. cerevisiae PF3D7_0210700 4.50E-16 Yes syntaxin, Qa-SNARE family (SYN17) 
Cvt
Atg11 S. cerevisiae PF3D7_1239800 9.80E-10 Yes conserved Plasmodium protein, unknown function
Atg11 S. cerevisiae PF3D7_0203000 1.00E-14 Yes conserved Plasmodium protein, unknown function
Other
OATL1 H. sapiens PF3D7_1320200 0.00084 Yes TBC domain protein, putative 
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information Interactors PlasmoDB expression data 
Genetic 
modification








PF3D7_1107300 Mass Spec: Trophozoite (Florens 2002)
Atg101 32, 33
DOES NOT have 
DUF1649, Val-rich or AAC RNA: Trophozoite/gametocyte
Nucleation
Vps34 32, 13
Mass spec: sporozoite (Florens), 
schizont. 
Vps15 26, 24
No WD but predicted 
myristolyated







Atg18 28, 67 FRRG and WD motif
Mass Spec: gametocytes, schizont, 
trophozoites, rings, merozoites, 
Atg9 25, 6 No transmembrane
Mass Spec: sporozoite, merozoite, 
schizont
Maturation
Atg4 31, 8 Mass spec: schizont (Treek & Sanders)
Atg8 40, 98
Mass Spec: merozoites, ring, schizont, 
gametocytes, sporozoites
Atg3 30, 93 RNA: trophozoite and gametoctes
Atg7 46, 29 RNA: schizont
Decrease in blood 
stage growth
Atg12 33, 75 RNA: trophozoite





Mass spec: ring, trophozoite, schizont, 
gametocyte
Atg22 39, 11
Mass spec: gametocytes 
(Silverstrini)RNA: Schizont and 
Gametocytes
Vps39 17, 8
Pfam: Vps39 e-value: 3.8e-
18 PF3D7_0936300 Mass Spec: gametocytes and schizonts
Sec22 30, 73
Mass Spec: trophs, merozoites, 
gametocytes, schizonts
VAMP8 24, 42 Pfam: synaptobrevin
AtVti1b 21, 47
Pfam: Vesicle transport v-
SNARE protein N-term 
Ykt6 39, 90
Mass spec: gametocytes, trophs, 
schizont, merozoite
Exophagy



















Mass spec: Schizont, gametocytes, 
trophozoite, sporozoite
Atg11 9, 8
3-4 coiled coiled. Pfam: 
Atg14 e-value:   2.8e-05 
(insignificant) PF3D7_1011400
Mass spec: gametocyte, sporozoite, 
schizont (Florens)
Mutant has  54% 
blood stage growth 
(Balue 2010)
Other




Table A.2. List of primers used for amplification and mutagenesis of constructs.   
 
  
























Table A.3. List of Atg8 and Atg3 constructs.  
 
P. falciparum Atg8 constructs Purpose 
His6-PfAtg8 Purification 
PfAtg8-His6 Prevent truncation purification 
His6-TEV-PfAtg8 Cleavage of His6 tag 
His6-PfAtg868-76!  (LD or LD1) 
Stability/PfAtg3 interaction studies (A-loop 
deletion) 
His6-RRR-PfAtg8 Promote crystallization 
His6-PfAtg8E44A/K45S/K46A Surface entropy reduction/PfAtg3 
interaction studies 
His6-PfAtg8C32I Prevent aggregation 
His6-PfAtg8C119S/C122S (DM) Prevent aggregation 
His6-PfAtg8C32I/C119S/C122S (CM) Prevent aggregation 
His6-TEV-PfAtg8CM Crystallization 
His6-PfAtg8CM/R37E/N39K PfAtg3 interaction studies 
His6-PfAtg8K47E W-site mutant 
His6-PfAtg8K19E/K47E W-site mutant 
His6-PfAtg8K19E/K47E W-site mutant 
His6-PfAtg8R27E W-site mutant 
His6-PfAtg8L49A W-site mutant 
MBP-TEV-PfAtg8 Enhanced expression 
MBP-TEV-PfAtg8CM Enhanced expression/crystallization 
MBP-TEV-PfAtg8C32I Single Cysteine mutant 
MBP-TEV-PfAtg8CM/Y112A/Y114A Lipidation assays 
MBP-TEV-PfAtg8G124C Lipidation assays 
MBP-TEV-PfAtg8CM/G124C Lipidation assays 
MBP-TEV-GFP-PfAtg8 ELISA binding assays 
MBP-TEV-GFP-PfAtg8CM ELISA binding assays 
His6-PfAtg8CM/K5A SUMOylation assays 
His6-PfAtg8CM/69-78! (LD2) Alternate A-loop deletion 
His6-PfAtg8CM/K47E CM/W-site mutant 
His6-PfAtg8CM/68-76! (CM/LD1) CM/A-loop deletion 
His10-TEV-AVI-PfAtg8CM Biotinylation – for SA SPR chip 
His12-TEV-PfAtg8 SPR Ni-NTA chip 
His12-TEV-PfAtg8CM SPR Ni-NTA chip 
His12-PfAtg8 SPR Ni-NTA chip 
His12-PfAtg8DM SPR Ni-NTA chip 
His10-PfAtg8CM SPR Ni-NTA chip 
His12-PfAtg8DM/K47E SPR Ni-NTA chip – W-site mutant 
His12-PfAtg8DM/I20R/K47E SPR Ni-NTA chip – W-site salt bridge 
His12-PfAtg8DM/F48E SPR Ni-NTA chip – mutant 
His12-PfAtg8DM/68-76!   SPR Ni-NTA chip – A-loop mutant 
P. vivax Atg8 constructs Purpose 




MBP-TEV-PvAtg8C32I Prevent aggregation 
MBP-TEV-PvAtg8C32I/C119S/C122S Prevent aggregation 
P. berghei Atg8 constructs Purpose 
His6-TEV-PbAtg8 Purification/Crystallization 
MBP-TEV-His6-PbAtg8 Purification/Crystallization 
Toxoplasma Atg8 constructs Purpose 
His6-EK-TgAtg8 (Dr. A. Sinai) Cleavable tag via enterokinase site 
MBP-TEV-TgAtg8 Crystallization 
H. sapiens LC3 Purpose 
MBP-TEV-LC3 Interaction studies 
 
P. falciparum Atg3 constructs Purpose 
His6-PfAtg3 Purification 
His6-TEV-PfAtg3 Cleavable tag 
PfAtg3-His6 Prevent truncations product purification 
MBP-TEV-His6-PfAtg3 Affinity purification 
MBP-TEV-GFP-PfAtg3 ELISA binding assays 
MBP-TEV-GFP-PfAtg3120-143! ELISA binding assays 
MBP-TEV-GFP-PfAtg3145-151! ELISA binding assays 
MBP-TEV-His6-PfAtg31-165 PfAtg8 interaction studies 
MBP-TEV-His6-PfAtg3166-319 PfAtg8 interaction studies 
MBP-TEV-PfAtg3 Cleavable with no leftover tag 
MBP-TEV-His6-PfAtg3L106A PfAtg8 interaction studies 
MBP-TEV-His6-PfAtg3W105A PfAtg8 interaction studies 
MBP-TEV-His6-PfAtg3W58A PfAtg8 interaction studies 
MBP-TEV-His6-PfAtg3W214A PfAtg8 interaction studies 
MBP-TEV-His6-PfAtg3WLLP/AAAA PfAtg8 interaction studies 
MBP-TEV-His6-PfAtg3W105R PfAtg8 interaction studies 
His6-PfAtg3191-262 PfAtg8 interaction studies 
His6-PfAtg3191-319 PfAtg8 interaction studies 
P. berghei Atg3 constructs Purpose 
His6-PbAtg3 Co-crystallization with PbAtg8 
Toxoplasma Atg3 constructs Purpose 
His6-TgAtg3 Co-crystallization with TgAtg3 
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Table A.4. Non-candidates from mass spectrometry-based PfAtg8 interactome study. Proteins 
identified in pulldown experiments not meeting criteria for specific for PfAtg8-sample. 
  
Ni-NTA GAP50
Identified Proteins (RecName) GI number MW  R2 R3 R1 R2 R3 R1 R3 R2 R3
acid phosphatase gi|124506908 45 kDa 0 0 0 0 0 0 100% 0 0
conserved Plasmodium protein gi|124801350 167 kDa 100% 100% 100% 100% 100% 100% 75% 100% 99%
elongation factor 1 alpha gi|124513850 49 kDa 100% 0 100% 100% 19% 100% 39% 100% 100%
elongation factor 2 gi|124809712 94 kDa 100% 0 0 100% 0 0 0 100% 0
Heat shock 70 kDa protein gi|226045 74 kDa 100% 0 100% 100% 0 100% 0 100% 0
Heat shock protein gi|124506906 72 kDa 100% 100% 100% 100% 100% 100% 99% 100% 0
pyruvate kinase gi|86171639 56 kDa 100% 0 100% 100% 0 100% 0 100% 0
hypothetical protein gi|124504769 475 kDa 98% 74% 93% 99% 98% 99% 61% 100% 78%
disulfide isomerase precursor gi|124512228 56 kDa 100% 74% 0 100% 0 0 0 100% 0
cysteine repeat modular protein 2 homologue gi|124511904 297 kDa 89% 0 50% 100% 0 100% 91% 88% 0
glyceraldehyde-3-phosphate dehydrogenase gi|124810131 37 kDa 100% 99% 0 100% 0 0 0 100% 0
merozoite surface protein 1, precursor gi|124507147 196 kDa 100% 0 0 100% 0 98% 0 100% 0
s-adenosylmethionine synthetase gi|124506992 45 kDa 50% 0 0 100% 0 0 0 100% 0
endoplasmin homolog precursor, putative gi|124806075 95 kDa 100% 74% 0 100% 0 0 75% 100% 0
rhoptry neck protein 3, putative gi|124807078 263 kDa 89% 97% 92% 100% 0 85% 61% 86% 97%
heat shock protein 86 gi|124511730 86 kDa 94% 58% 0 100% 0 0 73% 100% 0
tetQ family GTPase, putative gi|124806527 136 kDa 0 0 0 100% 0 0 0 94% 78%
eukaryotic initiation factor 5a, putative gi|124805478 18 kDa 0 0 100% 100% 0 100% 0 100% 0
dynein heavy chain, putative gi|124805409 692 kDa 0 0 0 0 0 0 100% 0 0
pyridoxine biosynthetic enzyme pdx1 homologue gi|86171362 33 kDa 0 0 0 100% 0 0 0 100% 0
reticulocyte binding protein 2 homolog B gi|13345189 383 kDa 31% 100% 0 86% 0 0 70% 100% 98%
polyadenylate-binding protein, putative gi|124806145 97 kDa 50% 0 0 100% 0 100% 0 100% 0
hypothetical protein gi|124506367 1121 kDa 0 74% 0 89% 0 100% 0 23% 0
histone H2B gi|124803500 13 kDa 0 74% 0 83% 75% 0 100% 0 0
thioredoxin peroxidase 1 gi|124809308 22 kDa 35% 0 0 100% 0 100% 0 0 0
chromosome associated protein gi|124505413 141 kDa 83% 100% 0 99% 0 0 0 86% 64%
conserved protein gi|124803477 49 kDa 0 0 0 100% 0 100% 0 0 0
peptidase, putative gi|124809816 89 kDa 0 0 0 100% 0 0 0 100% 0
Plasmepsin-2 gi|1172530 51 kDa 0 0 0 100% 0 0 0 82% 0
histone h2a gi|86171188 14 kDa 0 60% 81% 0 60% 85% 100% 0 40%
conserved protein, unknown function gi|124808875 33 kDa 0 0 0 100% 0 0 0 100% 0
haloacid dehalogenase-like hydrolase, putative gi|124802833 33 kDa 0 0 0 100% 0 0 0 88% 0
40S ribosomal protein S2B, putative gi|124802649 30 kDa 0 0 0 100% 0 0 0 82% 0
myo-inositol 1-phosphate synthase gi|124506155 69 kDa 0 0 0 100% 0 0 0 100% 0
60S ribosomal protein L13, putative gi|124801997 24 kDa 0 0 0 100% 0 80% 0 0 0
tubulin beta chain, putative gi|124802114 50 kDa 47% 0 0 0 0 0 0 100% 0
60S ribosomal subunit protein L18 gi|124513556 22 kDa 0 0 0 100% 28% 100% 0 0 0
60S ribosomal protein L12 gi|124506259 17 kDa 0 0 0 100% 0 100% 0 0 0
histone H3 gi|82541094 15 kDa 0 0 100% 0 0 0 100% 0 0
TCP-1/cpn60 chaperonin family gi|124804435 60 kDa 0 0 0 100% 0 0 0 50% 0
conserved GTP-binding protein gi|124511984 45 kDa 0 0 0 100% 0 0 0 50% 0
ubiquitin/ribosomal fusion protein uba52 homologue gi|124514026 15 kDa 0 0 0 100% 0 0 30% 0 26%
60S ribosomal protein L11a gi|124511928 20 kDa 0 0 0 100% 0 100% 0 0 0
hypothetical protein gi|124806088 24 kDa 0 100% 0 0 0 0 0 0 78%
asparagine-tRNA ligase, putative gi|124801179 71 kDa 0 0 0 100% 0 0 0 100% 0
hypothetical protein gi|124506449 525 kDa 0 100% 0 0 100% 0 0 0 0
cof-like hydrolase, had-superfamily, subfamily iib gi|124806216 33 kDa 0 0 0 100% 0 0 0 100% 0
60S ribosomal protein P1, putative gi|124803451 13 kDa 0 0 0 100% 0 85% 0 0 0
histone H4 gi|124803496 11 kDa 0 0 81% 0 0 0 100% 0 0
subunit of proteaseome activator complex gi|124506703 33 kDa 0 0 0 100% 0 80% 0 0 0
elongation factor 1-gamma gi|124513508 50 kDa 0 0 0 100% 0 0 0 100% 0
40S ribosomal protein S15 gi|124513116 17 kDa 0 0 0 63% 0 100% 0 0 0
60S Acidic ribosomal protein P2 gi|124504853 12 kDa 0 0 0 100% 0 85% 0 0 0
phosphoribosylpyrophosphate synthetase gi|124513270 49 kDa 0 0 0 100% 0 100% 0 0 0
eukaryotic translation initiation factor 3 subunit 7, putative gi|124802093 63 kDa 0 0 0 100% 0 97% 0 0 0
plasmepsin IV gi|124808170 51 kDa 0 0 0 100% 0 0 0 76% 0
eukaryotic translation initiation factor 2 gamma subunit, putative gi|124808285 51 kDa 0 0 0 0 0 50% 0 100% 0
dihydropteroate synthetase gi|124512570 83 kDa 0 0 0 50% 0 0 0 100% 0
early transcribed membrane protein gi|124506543 19 kDa 0 0 0 50% 0 0 0 100% 0
serine hydroxymethyltransferase gi|124806534 50 kDa 0 0 0 0 0 0 0 100% 0
histone h2b gi|124511826 14 kDa 0 0 0 0 0 0 100% 0 56%
alpha tubulin gi|124506627 50 kDa 89% 0 0 0 0 0 0 100% 0
adenosylhomocysteinase(S-adenosyl-L-homocystein e 
hydrolase) gi|124506339 54 kDa 0 0 0 0 0 0 0 100% 0




































Figure A.2. Binding of fragment 410 to the MBP-PfAtg3 CM3 chip. F408 (blue) and F410 (red) alone 
were injected in triplicate over the chip mimicking conditions from the Atg8-Atg3 inhibition SPR study. 








Figure A.3. Deconvolution of 2,3-dihydroxybenzaldehyde hit from first pass screen. Reactions with R1 
and R2 were set up with only one linker length corresponding to 2 to 5 carbons (OX1.2-OX1.5). A. 
Deconvoluted species, as well as original mixture was tested for inhibition of PfAtg8-PfAtg3 PPI with 
SPR. B. Deconvoluted species as well as R1 and R2 groups alone were tested for binding to PfAtg8 with 



















Figure A.4. Alignment of P. yoelii and P. falciparum Atg8. Sequences were aligned using MUSCLE 










Figure A.5. 1H-15N HSQC 2D spectrum of 15N-His6-PfAtg8CM. Each peak in the spectrum represents a 
backbone N-H group, or side-chain NH2 groups (boxed region shows a couple of NH2 peaks are indicated 
by dashed lines). 
  



























Figure A.6. Co-localization of PfAtg8 and ACP under high parasitemia. Antibodies specific for the 
apicoplast marker ACP were used to visualize the apicoplast in the FCR3 parasite line, grown to 26% 
parasitemia. Antibodies against TgAtg8 cross react with PfAtg8 (69) and show partial co-localization with 
PfAtg8 and ACP in the late trophozoite stage. Image z-stacks were deconvolved and presented as a single 




Figure A.7. PfAtg8 localization under PAH9 drug treatment. P. falciparum FCR3CSA was treated with 
DMSO or 5 µM PAH9 for six hours and localization of PfAtg8 and PfEMP1 in blood stages was assayed 




 Figure A.8.  Sequence alignment of various PfEMP1 ATS domains. PfEMP1 ATS sequences 
representing all the clusters were aligned with cluster omega. The putative AIM is shown with cyan box. 
Asterisks denote PfEMP1 identified as candidate PfAtg8 interactors. Diamond denotes Var2csa sequence 
from 3D7 strain. ATS domains were determined to be sequence following predicted TM domain and 
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